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Vaccination programs using live whole cell vaccines are presently being used to
control outbreaks and to help protect flocks from field strains of Mycoplasma
gallisepticum. The primary goal of the present study was to investigate the effects of a
ts11-strain M. gallisepticum inoculation alone, and in conjunction with F-strain M.
gallisepticum overlays at 22 or 45 weeks of age during lay.
In this study, it was shown that a pre-lay ts11 vaccination had a broad range effect
on the physiology of the commercial layer without affecting overall performance. The
timing of an overlay vaccination using F-strain M. gallisepticum during lay also had
varied effects on physiological parameters without affecting overall performance. This
study indicates that using ts-11-strain M. gallisepticum in conjunction with F-strain M.
gallisepticum does not negatively affect laying hen
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CHAPTER I
INTRODUCTION
Mycoplasma gallisepticum, the pathogen responsible for chronic respiratory
disease in chickens is primarily a respiratory pathogen of meat-type chickens and turkeys,
and a reproductive pathogen of table egg chickens. Due to the ease of disease
transmission resulting systemic infection results in great economic loss worldwide.
Decreased egg production (EP) and hatchability, downgrading and condemnation of
carcasses, and reduced feed conversion can result from M. gallisepticum infections
(Yoder and Hofstad, 1964; Domermuth et al., 1967; Patterson, 1994).
Vaccination programs using live whole cell vaccines are presently being used to
control outbreaks and to help protect flocks from field strains of M .gallisepticum. The
F-strain M. gallisepticum vaccine strain is less virulent than many of the field strains and
has a lower bird to bird transmission rate, yet is able to displace the more virulent stains
of M. gallisepticum (Levison and Kleven, 1981; Kleven et al., 1990). The F-strain M.
gallisepticum vaccine, however, is not totally apathogenic and has been reported to infect
M. gallisepticum free birds and turkeys (Evans et al., 1992, Ley et. al., 1997). More
recently, apathogenic whole cell live vaccines ts11-strain M. gallisepticum and 685-strain
M. gallisepticum have been licensed for use in layer chickens. These vaccines show
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virtually no bird to bird transmission, but have not been proven to displace wild type M.
gallisepticum (Kleven et al., 1998). Furthermore, these strains may not confer continued
protection as does the F-strain throughout lay (Yoder, 1978, 1991; Mohammed et al.,
1987).
There are possible benefits of using a prelay ts11 M. gallisepticum inoculation in
conjunction with F–strain M. gallisepticum inoculations during lay to effectively protect
flocks against field strain MG infections, while reducing possible subsequent depressions
in EP due to a pre-lay F–strain M. gallisepticum inoculation. Commercial operations
may acquire flocks already inoculated with ts11 M. gallisepticum, but desire to continue
using the F–strain M. gallisepticum inoculation regime familiar to them. Therefore, the
goal of this study was to investigate the effects of a ts11 M. gallisepticum .inoculation
pre-lay overlaid with F–strain M. gallisepticum inoculation during lay on the
performance, blood, internal egg and eggshell, and reproductive and digestive organ
characteristics of commercial layers.
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CHAPTER II
REVIEW OF LITERATURE
The Avian Reproductive System
The avian reproductive system initially begins with both left and right ovaries and
oviducts; however, the primordial germ cells to the ovaries begin the process of
asymmetrical distribution by day four of incubation. This is followed by initiation of
regression of the right oviduct by Day 10. By the time the bird is an adult, (except for
rare occasions); only the left ovary and oviduct are functional (Romanoff and Romanoff,
1949; Kinsky, 1971). A chick will produce approximately 280,000 oocytes of which
only approximately 200-500 will mature and be ovulated during a bird’s life span.
Oogenesis is terminated at hatch. These oocytes (follicles) are governed by what is
known as a follicular hierarchy. This follicular hierarchy functionally produces only 4-6
follicles (ova) which become large yolk filled mature follicles measuring approximately
40 mm in diameter, a larger number of smaller yellow follicles and numerous small
yellow white follicles.
Follicle production is driven by the follicle stimulating hormone (FSH), while the
follicle hierarchy is under the control of estrogen which is secreted by the mature ovary.
Secretion of estrogen induces the secretion of lutenizing hormone (LH), which then
2

controls the ovulation of mature follicle from the ovary. Follicles are ovulated in the
order of the follicular hierarchy. The avian oviduct has five distinct regions;
infundibulum, magnum, isthmus, shell gland, and vagina. The infundibulum is a funnel
shaped part of the oviduct, (not attached to the ovary), which catches the ovulated ova.
The ova remain in the infundibulum for approximately 18 minutes (Warren and Scott,
1935).
The infundibulum is the site where fertilization can occur and where the first
layer of albumen is deposited (Gilbert, 1979). The ovum then proceeds to the magnum,
which is the largest portion of the oviduct, measuring approximately 33 cm. The magnum
is highly glandular consisting of tubular glands that are responsible for the production of
ovotransferrin and ovomucoid, and the site where the chalazae and the majority of
albumen are formed (Aitken, 1971; Tuohimaa, 1975). Albumen is secreted in the
magnum in response to the pressure of the yolk and the amount of albumen is believed to
be related to the size of the yolk suggesting that the smaller yolk stimulates less albumen
resulting in smaller egg size (Sturkie and Mueller, 1976). The ovum remains in the
magnum for approximately 2-3 hr where the initiation of calcium secretion occurs (Eastin
and Spaziani, 1978). Haugh Unit scores are a means to evaluate this inner egg quality,
specifically albumen. This suggests that the inner egg quality is determined by the health
and functionality of the magnum (Branton et al., 1988) the ovum continues moving into
the isthmus which is more muscular and less glandular, containing tubular gland cells
overlaid with epithelial cells, where it will remain for approximately 2 -3 hr. The isthmus
is the site of formation of both the inner and outer shell membranes. The ovum then
enters the uterus, a highly muscular structure also known as the “shell gland” which is
3

lined with both tubular and unicellular goblet cells (Johnson, 1986). This is where the
egg begins what is termed the “plumping” process where salts are absorbed. The egg
remains in the uterus for approximately 26 hr. Calcification takes approximately 15 hr
and pigmentation approximately 5 hr (Warren and Conrad, 1942). Thus, the uterine
function/dysfunction should be reflected by ESS, shell thickness, and pimpling (Branton
et al., 1988)
Blood and meat spots, sometimes observed in the yolks are attributed to
intrafollicular hemorrhage; possibly resulting from increase in either blood pressure or
ovarian capillary fragility. The final portion of the oviduct is the vagina where
ovipositioning of the egg occurs (Johnson, 2000).

Hormonal Influences on Avian Reproduction
The hormones progesterone and estrogen can found in their highest concentration
in the preovulatory follicles, conversely concentrations of testosterone decrease in the
larges preovulatory follicles 6-8 hours before ovulation (Shahabi et al., 1975).
Approximately 4 -6 hours prior to ovulation, a peak occurs in plasma concentrations of
lutenizing hormones (Lague et al., 1975; Johnson and van Tienhoven, 1980; Etches and
Cheng, 1981). This LH peak coincides with peak in progesterone (Etches and Cheng,
1981), and is thought to be a necessary part of ovulation. Etches and Cheng (1981)
asserts that there is a second peak of LH at 14–16 hours prior to ovulation. Testosterone,
which is secreted from at least four of the largest follicles, returns to the peak
preovulatory concentration 6-10 hours before ovulation.
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Ovulation can occur without testosterone or DHT indicating that they are not
directly involved in ovulation (Johnson, 1986). Cortecosterone has both a daily and
peaks with ovoposition, but does not increase in relationship with ovulation. (Johnson
and van Tienhovek, 1981). The follicle stimulating hormone (FSH) concentration and
the binding to ovarian tissue peaks 15 hours prior to ovulation (Seanes et al., 1877;
Etches and Cheng, 1981).
Two different kinds of calcium can be found in circulating blood; non-diffusible
protein-bound calcium (unionized) and diffusible ionized calcium. Plasma calciumbinding proteins, vitellogenin, and albumen bind with the non-diffusible calcium (Guyer
et al., 1980). Estrogen increases the amount of these binding proteins; thus, increasing
blood calcium levels (Bacon et al., 1980). Adequate amounts of calcium must be
provided in the diet or a significant decrease in egg production can occur. Ovary
regression also occurs 6-9 days necessary dietary calcium is not provided (Taylor et al.,
1962; Luck and Scanes, 1979). Layers will voluntarily increase calcium consumption
when the egg enters the uterus and when the egg-shell calcification process occurs
(Mongin and Sauveur, 1974).
Photoperiods are necessary for layer egg production. Although hens can continue
to lay in the complete darkness, a decrease in egg production will occur (Wilson and
Woodward, 1958; Morris, 1968). The ovarian development is most impacted by 12-14
hours of light; however, optimal egg production has been achieved by up to 18 hours of
light.
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Composition of the Avian Egg
As describe above, the mature egg consists of 3 main parts; eggshell, a multilayer
albumen, and yolk. There is a thick inner layer of albumen is surrounded by a thin inner
and outer layer of albumen. The thick albumen layer consists of ovomucin which
increases the viscosity of the mucin. Approximately 60% of the total egg weight is
albumen weight. There are approximately 40 different proteins in the albumen; however,
the ovalbumen is the major protein involved. The egg yolk is surrounded by the vitellin
membrane which separates it from the albumen. The egg yolk also is made up of two
layers. The deep yellow layer, which is formed during the daylight hr and the light
yellow layer, is formed during the night hr. The egg yolk consists of lipoproteins and rich
lipids.
These lipids make up approximately 60% of the total yolk weight. Lipids found
in the yolk are triglycerides, phospholipids, cholesterol and cerebroside. The major fatty
acids found in the egg yolk are oleic, palmic, linoleic, and predominantly stearic and
palmic fatty acids. They make up approximately 38% of the egg, the calcified portions,
can be divided into three layers; the mammilary knob layer formed from the outward
crystallization of the mammilary core, the palisade layer and the shell matrix. The egg is
then covered by a thick waxy covering that is believed to protect the egg from moisture
loss.

Avian Lipid Metabolism
Fatty acids can be characterized as saturated and unsaturated, as well as, essential
or nonessential. Avian lipid requirements are relatively small only requiring a small
6

amount of the few fatty acids that cannot be synthesized by the bird’s body (arachadonic,
linolenic, and linoleic). These fatty acids that cannot be synthesized are considered to be
essential fatty acids. Dietary supplements of linoleic acid can satisfy the need for both
linoleic acid and arachodonic acid since synthesis of arochodonic acid is possible from
linoleic acid. Fatty acid synthesis mostly occurs in the liver. Synthesis of fatty acids in
the bird is under two major enzyme systems. Acetyl-Co A carboxylase (a biotin
dependent enzyme) is first and the multienzyme system fatty acid synthetase is the
second (Parkhurst and Mountney, 1987; Kleven, 2003).
Lipase activity occurs in the small intestine, as well as, the stomach where
triglycerides are hydrolyzed to diglycerides, monoglycerides, fatty acids, and glycerol
(Johnson, 1986). During digestion, micelles are formed and eventually absorbed into the
small intestine Cholecystokinin induces pancreatic enzyme secretion in response to lipid
entrance into the digestive tract (Dockray, 1975). The small intestine has villi which
absorb fatty acids while the lipids are transported by the portal blood system as
portomicrons after being esterfied (Bensadoun and Rothfield, 1972; Frazer et al., 1986).
Various hormones regulate lid metabolism.
Glucose is the end product of carbohydrate digestion and becomes a major
precursor of lipids. Glucagon and insulin are essential factors in lipogenesis regulation.
Glucagon affects lipolytic and antilipogenic hormones and insulin stimulates lipogenesis.
Avian pancreatic peptide reduces the concentration of circulating free fatty acids and
partially suppresses lipolysis by glucogon. Insulin inhibits the release of glycerol and
frees fatty acids in adipose tissue and also stimulates the conversion of glucose to fat by
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stimulating the lipoprotein lipase, incorporation of circulating triglycerides into cells
increases.

Mycoplasma gallisepticum Structure and Pathology
Mycoplasmas are members of the taxonomic class Mollicutes, and are among the
smallest and simplest known pleiomorphic microorganisms (Panangala et al., 1992; Wise
et al., 1992) capable of self-replication (Razin, 1981). Mycoplasma gallisepticum is an
infectious gram negative bacterium (Razin and Freundt, 1984) that is bound by a plasma
membrane, lacks a cell wall (Kleven, 1998) , and is able to infect entire flocks. Colonies
are approximately 1 mm in diameter and have a characteristic “fried-egg” appearance
when viewed through a microscope (Kleven, 1998) with a genomic size of about 5 x 108
daltons (ranging from about 600 to 1300 kbp). This small genome size allows very
limited metabolic capabilities.
Researchers have examined the mechanism(s) of Mycoplasmas adherence to the
host cells in order to understand the initiation of disease pathogenesis and develop a
treatment that would prevent the adherence and thus inhibit infection. This mechanism is
well described by Razin (1985). Using electron microscopy, it was determined that an
attachment organelle or tip structure (Uppal and Chu, 1977; Tajima et al., 1979; Razin et
al., 1980; Kirchhoff et al., 1984; Levisohn, 1984; Maniloff and Quinlan, 1973), was
present which allows Mycoplasma to bind to sialoglycoproteins (Glasgow and Hill, 1980;
Bredt et al., 1981; Kahane et al., 1984). These extracellular parasites attach to the host
epithelium via the external bleb (attachment organelle) for nutritional support which can
cause disease by causing host cell injury. Mycoplasmas have a small amount of motility
8

that may contribute to their adherence to various structures in vivo (Razin, 1984).
Although adherence to epithelial cells is not singularly the cause of pathogenicity, it tends
to play an important role. Research has proven that MG organisms are able to adhere to
the epithelial surface of the respiratory tract of chickens by their terminal bleb structures
(,Maniloff and Quinlan, 1973). Although it has been determined that the body is able to
recognize and mount an immune response to Mycoplasmas, (Kerr et al., 1970), they can
evade the host immune. Mycoplasma has an antigenic diversity mechanism (Panangala,
et al., 1992; Wise, 1992) Antigenic diversity of M. gallisepticum strains has also been
reported (Panagala, et al., 1992).
This mechanism of antigenic diversity allows M. gallisepticum to circumvent the
host immune response to specific epitopes; thereby, leading to chronic infection
characteristic of M. gallisepticum. This directly impacts the virulence of Mycoplasmas as
organisms evade nonspecific defense mechanisms (Howard and Taylor, 1979; Davidson
et al., 1988). Different antigenic profiles in MG are due to the differential expressivity of
major surface antigens (Garcia et al., 1994). Upon entering the host and multiplying,
these organisms evade the host’s immune system by phenotypic switching (phase shifts),
then escape to infect new hosts.
Although, the primary location of M. gallisepticum infection colonization is the
respiratory system, the invasion of other organs is possible due to their ability to migrate
through the blood stream from the mucosal membrane of the respiratory system to other
organs via attachment to erythrocytes (Winner et al., 2000). M. gallisepticum is capable
of infecting entire flocks and tends to be more severe in young birds and in cold weather
(Ley and Yoder, 1997).
9

Due to its minimal genomic size, and lack of cell wall, Mycoplasma cannot
survive outside its host for long periods of time and are susceptible to cleaning and
disinfecting agents (Kleven, 2003). Viability of M. gallisepticum is dependent on the
strain and the conditions at which MG contaminated materials are held (Chandiramani et
al., 1966). It can be transmitted bird to bird through horizontal and vertical transmission,
as well as, through the hatching egg which is the major route of infection for the next
generation (Kleven, 1981; Glisson and Kleven, 1984).
It has been shown that maternal antibodies inhibit multiplication of M.
gallisepticum organisms in the egg in the beginning of the incubation period, but do not
kill the organisms. Eggs from effected chickens had the highest rates of mortality at the
end of the incubation period, suggesting the multiplication of the Mycoplasmas inhibit
the embryo’s development (Levinsohn et al., 1985). Once a bird is infected, it is
considered to be infected for life and is able to infect others in a flock (Brown et al.,
1995)
Respiratory infections caused by Mycoplasma are often mild unless accompanied
by secondary infections (Kerr and Olson, 1967). Although M. gallisepticum infections
are more prevalent in the respiratory system, they can become systemic over time, and
are not fatal unless a secondary infection is present. Symptoms of M. gallisepticum are
often confused by symptoms from secondary infections. Respiratory disease in poultry
has a complex etiology in which various species of Mycoplasmas are only a single factor.
Chronic respiratory infections associated with M.gallisepticum become more severe and
adversely affect producer profit if the disease is complicated with Newcastle’s Disease or
Infectious Bronchitis exposure (Mohammed et al., 1987; Patterson, 1994). Mycoplasma
10

gallisepticum infection is one of the costliest diseases confronting the poultry industry
(Yoder, 1978). Many birds may have M .gallisepticum present but the infection remains
dormant until these birds are exposed to a stressor, the organism is then likely to spread
throughout the flock.
As mentioned, the colonization and infection with M. gallisepticum is most often
occurs in the air sacs of the avian respiratory tract causing air sacs to become cloudy and
filled with mucus. As the disease persists, this mucus develops a yellow color and a
cheesy consistency and may result in development of lesions in the respiratory tract in
birds (Trampel and Fletcher, 1981; Nunoya et al., 1987, 1995). If M. gallisepticum
infection is complicated by E. coli, extensive pneumonia and air sacculitis are common,
along with fibrinopurulent pericarditis and perihepatitis (Gross, 1990). Young birds are
more likely to show signs of clinical disease after exposure to more virulent strains of
Mycoplasmas (Jordan, 1972).

Mycloplasma Isolation and Identification
Researchers have documented that M. gallisepticum can be cultured from
tracheal, air sac, lung, and sinus exudates (Kleven and Yoder, 1989),as well as choanal
cleft (Branton et al., 1984; Brown et al., 1995) brain (Chin, 1991) oviduct (Yoder and
Hofstad, 1964), liver ,spleen, uterus, vagina, (Suhu and Olson, 1976) and cloaca (Amin
and Jordan, 1979; MacOwan, 1983) of birds. Isolation, identification, and serological
tests, such as serum plate agglutination (SPA), hemagglutination inhibition (HI), and
enzyme linked immunosorbent essay, ELISA and fluorescent antibody (FA) tests are
used to diagnose M. gallisepticum infections. Because the SPA test is quick, relatively
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inexpensive, and sensitive, it has been widely used as an initial screening test for flock
monitoring and serodiagnosis. The HI test has been commonly used to confirm reactors
detected by SPA or, more recently, ELISA. It is vital that M. gallisepticum infection
diagnosis is accurate, because false positives or negative results can lead to great
economic loss.

Effects of M. gallisepticum on Layer Performance
Egg producers experience lost revenues from poor feed conversion, decrease body
weight (BW), and increased medication costs, in addition to drops in EP and poor egg
quality (Mohammed et al., 1987; Patterson, 1994). It is thought the reduced feed
consumption of infected layer hens may affect the necessary components of essential
dietary factors necessary to sustain adequate egg formation and egg production (Burnham
et al., 2002a). Birds infected with wild type M. gallisepticum have a drastic decrease in
EP; therefore, vaccination programs and intense bio-security measure are vital to prevent
substantial economic loss to egg facilities. Naturally infected flocks are shown to
produce as many as 16 fewer eggs per hen per year than M. gallisepticum -negative
flocks (Carpenter et al., 1981).

Control of Mycoplasma Infection
Eradication of M. gallisepticum is the ultimate goal for the poultry industry;
however, in multi-age layer complexes, it is not economically feasible (Yoder, 1978).
Although the poultry industry has been able to reduce the number of Mycoplasma
infected birds, the ubiquitous nature of M. gallisepticum results in continuation of high
12

percentages of infected layers. A number of antibiotics have been used treat M.
gallisepticum infected birds to minimized EP losses. M. gallisepticum is susceptible to a
number of antibiotics: tylosin, tiamulin, gentamicin, tetracycline, streptomycin,
erythromycin, spiromycin, valnemulin, enrofloxacin, lincomycin, and spectinomycin
(Ose et al., 1979; Jordan et al., 1998; Timms et al., 1989).
Total eradication of Mycoplasma is the ideal; however, depopulation and
disinfection of multi-age layer houses is too costly and impractical, the best solution in
this case may be to establish an M. gallisepticum vaccination program (Bermudez and
Kalbac, 1988). Vaccination programs, which stimulate the development of immunity to
Mycoplasmas, are commonly practiced for protection in animals (Barile, 1985).
Presently M. gallisepticum strains F, 685, and ts11 are the three live-attenuated vaccines
in use. Use of live vaccines helps prevent large production losses when used on multiage
layer facilities where M. gallisepticum is known to be present.

Effects of F- strain M.gallisepticum Vaccine on Layer Performance
Vaccination with F-strain M. gallisepticum has been predominantly used by
commercial layers facilities maintaining multi-age layer facilities for the following
reasons: it was the first live vaccine, USDA licensed, (Branton et. al., 1999), it has been
proven to displace more virulent strains and wild-type M. .gallisepticum, and it has a
lower transmission rate (Ley et al., 1997). Vaccination of young layers which have the
potential to contract M. gallisepticum may increase their production rates. F-strain M.
gallisepticum has been evaluated as a means of counteracting reductions in EP in
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multiple-age egg-layer complexes caused by infections with wild or field strains of M.
gallisepticum (Carpenter et al., 1981; Lin and Kleven, 1982; Hildebrand et al., 1983).
Inoculations with F-strain M. gallisepticum between 8 and 18 wk of age allow a
pullet to receive a mild infection and recover before coming into EP (Yoder et al., 1984).
Birds vaccinated with F-strain M. gallisepticum appear to be protected against wild field
strains which cause greater EP losses (Levisohn and Kleven, 1981; Kleven et al., 1990).
M. gallisepticum F-stain vaccine has strengths; however, it is not completely apathogenic
(Lin and Kleven, 1982) and the spread to M. gallisepticum-free turkey and chicken farms
has been reported. In situations where eradication appears unobtainable, controlling the
production loses appears to be the only viable alternative (Mohammed et al., 1987;
Patterson, 1994). Branton et al., (1997) reported that EP and other egg characteristic in
birds inoculated with F-strain M. gallisepticum at 10 wk of age were not significantly
different than controls. It has, however, been proven that F-strain M. gallisepticum given
late in lay does reduce EP. In a more recent report by Burnham et al., (2002a), using
birds inoculated at 12 wk of age, EP was reported to be significantly different in the Fstrain vaccinated birds compared to the controls. Burnham et al., (2002a) reported that
onset of lay was delayed and that a significant decrease in EP occurred. It was reported
that inoculated hens had fewer mature ovarian follicles and a decreased magnal, isthmal
and vaginal proportion of the reproductive tract at trial termination (60 wk) compared to
F-strain M. gallisepticum free hens (Burnham et al., 2002a). Burnham et al., (2003b)
suggested that the establishment of systemic F-strain M. gallisepticum infections and long
term changes were the result of the disease rather than the F-strain M. gallisepticum
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vaccination. To avoid careless use of F-strain M. gallisepticum vaccine, its use is under
the supervision of official state veterinarians or regulatory agencies.

Effects of ts11 and 685- strain M. gallisepticum Vaccines on Layer Performance
More recently apathogenic ts11 and 685 M. gallisepticum vaccines have been
licensed for use in the United States. These strains are not vertically (bird to egg) or
horizontally (bird to bird) transmissible; however, they have not been proven under
commercial conditions to have the ability to displace wild type or more virulent strains of
M. gallisepticum (Turner and Kleven, 1998).
Branton et al., (2000) reported that under ideal conditions when ts11 vaccine
given was given pre-lay ovaries and oviducts functioned similarly to control hens.
Kleven et al., (1998) reported that all three of the live vaccine strains colonized the upper
respiratory tract, but that re-isolation of 685 strains was inconsistent. They reported that
serological response to F-strain M . gallisepticum was strongest and ts11 strain responses
were intermediate, and that 685 responses were very weak. Kleven et al., (1998) also
reported that F-strain vaccine readily displaces the more virulent R-strain M.
gallisepticum, while ts11 and 685 vaccine strains show no ability to displace the more
virulent R strain under the conditions of the experiment.

Effects of ts11 and F -strain M. gallisepticum on the Blood, Egg Yolk, Digestive, and
Reproductive Organ Characteristics of Laying Hens
No information is available in the literature for blood, digestive and organ
characteristics for birds inoculated with ts11- strain M. gallisepticum; however, Burnham
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et al.,(2003a) in trials where birds were vaccinated with F-strain vaccine at 12 wk of age
whole blood hematocrit (HCT) increased at 8 wk after challenge suggesting a
compensatory polycythemic response to the F-strain vaccination but levels returned to
those of the controls, indicating that the birds adjusted through other physiological means
to the F-strain vaccination stressor. When a stressor such as F-strain M. gallisepticum is
introduced, triglycerides (ST) may become elevated in response to the infection. An
elevation in ST is known to be a common response to the presence of infectious disease
agents (Guyton and Hall, 1996). Burnham et al., (2000) reported significant changes in
HCT, plasma protein (PP), and serum cholesterol (SC), ST, and calcium (SCA) at some
point when F-strain vaccine was given alone. M. gallisepticum has also been shown to
affect the eggshell forming mechanisms (Domermuth et al., 1967; Burnham et al.,
(2003b) has also asserted that F-strain M. gallisepticum infection affects yolk lipid
(significantly higher at wk 32 and 44, and lower at wk 48) and cholesterol concentrations
(decreased at wk 22) as well as fatty acid composition. Yolk lipid concentration
differences may be due to adaptations to infection, where the yolk fatty acid
concentrations are indicative of changes in liver lipid synthesis. While the effects of Fstrain M. gallisepticum on performance are noted by Burnham (Burnham et al., 2002a)
among others, 685-stain M. gallisepticum is lacking in literature documenting its effect
on performance (Branton et al., 2002).
In a study by Peebles et al., (2007), also using the F-strain a significant increase in
fatty liver hemorrhagic syndrome (FLHS), as well as, increase in ovarian follicular
regression, and decrease in isthmal and vaginal properties of the reproductive tract were
observed for birds vaccinated with F-strain vaccine at 12 verses 22 wk Burnham et al.,
16

(2002b). Peebles et al., (2007) reported lower magnum weight in birds vaccinated with
F-strain vaccine at 12 verses 22 wk. Relative duodenal length was also decreased in bird
given the F-strain at 22 wk verses 12 wk.
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CHAPTER III
EFFECTS OF TIME SPECIFIC F-STRAIN MYCOPLASMA GALLISEPTICUM
INOCULATION OVERLAYS ON PRE-LAY TS11-STRAIN M.
GALLISEPTICUM INOCULATION ON PERFORMANCE
CHARACTERISTICS OF COMMERCIAL LAYING
HENS
ABSTRACT
Mycoplasma bacteria are virtually ubiquitous in layer chicken flocks and M.
gallisepticum is the species of greatest concern to commercial egg producers. Live M.
gallisepticum vaccines were initially approved by the USDA for use in commercial layers
in 1988 to help control M. gallisepticum outbreaks. In the present study, 2 trials were
conducted to determine the effects of 2 currently available live Mycoplasma vaccines
(ts11- and F-strains) when used together. The following 4 inoculation treatments were
utilized: 1) sham inoculation at 10 wk of age, 2) ts11 at 10 wk, 3) ts11 at 10 wk overlaid
by F at 22 wk, and 4) ts11 at 10 wk overlaid by F at 45 wk. In each trial at various ages
between 18 and 57 wk of age, hen mortality; BW; egg weight; egg production; eggshell
breaking strength; incidences of egg blood spots, egg meat spots, and eggshell pimpling;
and eggshell weight per unit of surface area were assessed. The effects of inoculation
treatment on egg weight at 27, 37, and 38 wk were inconsistent and variable. Eggshell
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pimpling and egg blood spot incidences at 56 wk were highest in eggs belonging to the
ts11 at 10 wk / F at 45 wk group. Despite increases in pimpling and blood spot
incidences very late in production due to the tsll at 10 wk F at 45 wk treatment,
performance in layers was not adversely affected by a 10 wk ts11 inoculation alone or in
conjunction with subsequent overlay inoculations of F during lay. It is, therefore,
suggested that the 10 wk inoculation of commercial layers with ts-11 may reduce the
negative impacts of a pre-lay F inoculation on performance, as reported in earlier studies,
while providing protection against subsequent field strain M. gallisepticum infections.
Furthermore, the ts-11- and F-strain M. gallisepticum treatment combinations may
overcome some of the inadequacies that prelay ts-11- or F-strain M. gallisepticum
vaccines may have when given independently.
(Key words: commercial layer, egg production, egg quality, F-strain Mycoplasma
gallisepticum, ts11-strain Mycoplasma gallisepticum)

INTRODUCTION
Mycoplasma gallisepticum, the pathogen responsible for chronic respiratory
disease in chickens, continues to be a concern to commercial table egg producers
maintaining multi-age layer houses. Once a bird is infected with M. gallisepticum, it is
considered to be chronically infected for life (Brown et al., 1995). Primarily a respiratory
pathogen of meat-type chickens and turkeys and a reproductive pathogen of table egg
chickens, M. gallisepticum results in great economic loss worldwide due to its ability to
systemically infect individual birds and the ease at which it is transmitted between birds.
Decreased egg production (EP) and hatchability, downgrading and condemnation of
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carcasses, and reduced feed conversion can result from M. gallisepticum infections
(Yoder and Hofstad, 1964; Domermuth et al., 1967; Patterson, 1994).
Vaccination programs are presently being used to help protect flocks from field
strains of Mycoplasma. Three live vaccines are commercially available for use in the
United States. The first live M. gallisepticum vaccine, referred to as F-strain, was
approved for use in commercial table egg chickens by the USDA in 1988 (Branton et al.,
1999). The F-strain M. gallisepticum vaccine strain is less virulent than many of the field
strains of M. gallisepticum and has a lower vertical transmission rate, yet it is able to
displace the more virulent stains of M. gallisepticum (Levisohn and Kleven, 1981;
Kleven et al., 1990). Continuous use of F-strain M. gallisepticum vaccines for
replacement flocks in multi-age commercial layer facilities has been shown to protect
these flocks from field strains (Kleven et al., 1990). The F-strain M. gallisepticum
vaccine, however, is pathogenic to turkeys, and is not approved or licensed for use in
poultry other than commercial layers. In a controlled study in biological isolation units,
early vaccination of commercial layers with F-strain M. gallisepticum did not adversely
affect EP (Branton et al., 1997). Anecdotal evidence from producers that have used Fstrain M. gallisepticum has also shown that no adverse effects on EP occur when F-strain
M. gallisepticum vaccinations are provided pre-lay (personal communication, Jack Self,
VP of operations, Cal Maine Foods, Inc.). However, some field studies have determined
that F-strain M. gallisepticum vaccination can reduce EP when compared to Mycoplasmafree birds (Carpenter et al.,1981; Mohammed et al., 1987; Branton et al., 1988). More
recently, apathogenic ts11-strain M. gallisepticum and 685-strain M. gallisepticum live
vaccines have been licensed for use in layer chickens. These vaccines show virtually no
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bird to bird transmission, but have not been proven to displace wild type M. gallisepticum
(Kleven, 1998). Furthermore, these strains may not confer continued protection as does
the F-strain throughout lay (Yoder, 1978, 1991; Mohammed et al., 1987). More testing is
needed to determine if combinations of vaccines can lessen the adverse impact of prelay
F-strain M. gallisepticum vaccinations on layer performance when given alone.
Therefore, the objective of the current study was to determine the effects of pre-lay ts11strain M. gallisepticum inoculations and time specific F-strain M. gallisepticum
inoculation overlays administered during lay on the performance characteristics of
commercial laying hens.

MATERIALS AND METHODS

Pullet Housing and Management
Two trials were performed using Hy-Line W-36 pullets that were obtained at 1 d
of age from a commercial source that was monitored and certified free of both M.
gallisepticum and M. synoviae (USDA-APHIS-VS, 2003). Chickens were vaccinated at
10 d of age for infectious bursal disease via the drinking water. At 5 wk of age, 20
randomly selected chickens were tested for antibodies to both M. gallisepticum and M.
synoviae using both the serum plate agglutination and the hemagglutination-inhibition
tests (Yoder, 1975) and swabs were obtained from the choanal cleft (Branton et al., 1984)
and placed into tubes containing Frey’s broth medium (Frey et al., 1968) supplemented
with an additional 0.15 thallium acetate and 106 IU penicillin-G/mL. Tubes were
incubated at 37 C for 30 d or until the phenol red indicator reaction occurred in the
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media. A sample from those that changed color was then inoculated onto Frey’s-based
agar and incubated at 37 C. Colonies with morphology suggestive of Mycoplasma species
were examined by an agar plate fluorescent antibody test (Baas and Jasper, 1972) that
used direct labeling of colonies stained with anti-F-strain M. gallisepticum polyclonal
antibodies produced in rabbits and labeled with fluorescein isothiocyanate (Kleven,
1981).
Pullets were placed on clean dry litter in a conventional house until 10 wk of age.
A daily artificial lighting schedule followed a 13 L:11 D cycle. One 75-W incandescent
light bulb was used to illuminate each 8.4 m2 of floor space, providing a calculated
intensity at bird level of 35.5 lx. Feed and water were provided for ad libitum
consumption in each trial. At 10 wk of age, 11 pullets were randomly selected and placed
in each of 16 negative pressure fiberglass biological isolation units (1.16 m2). The units
were housed in a previously described poultry disease isolation facility (Branton and
Simmons, 1992). Hen numbers were reduced to 10 per unit at point-of-lay (22 wk of
age) so that bird density was 0.116 m2 / bird for the duration of each trial. At 18 wk of
age, the length of the artificial lighting schedule was increased 15 min/d until a cycle of
16 h and 15 min of light per 7 h and 45 min of dark was achieved. Chickens were
maintained on that schedule through the remainder of each of the trials. For the entirety
of each trial, chickens had ad libitum access to feed and water. Pullet and layer diets
were formulated to meet or exceed NRC (1994) recommendations. Ingredient
percentages and calculated analyses of the diets were as described by Burnham et al.,
(2002). No medications were administered during either trial.
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Treatments
Four experimental treatment groups were used. Each treatment group consisted
of 4 isolation units containing 10 birds each for a total of 40 birds per treatment group.
Treatment one (Controls) received no M. gallisepticum inoculation but were shaminoculated via eye-drop in the right eye with sterile Frey’s media. Treatment 2 contained
birds that were eye-drop vaccinated in the right eye with ts11-strain M. gallisepticum at
10 wk of age (ts11/10). Birds belonging to treatment 3 received ts11-strain M.
gallisepticum via eye-drop at 10 wk of age followed by a 22 wk overlay vaccination via
eye-drop in the left eye with F-strain M. gallisepticum (ts11/10-F/22). Treatment 4
consisted of birds given ts11 strain M. gallisepticum at 10 wk of age via eye drop in the
right eye followed by a 45 wk overlay vaccination of F-strain M. gallisepticum via eye
drop in the left eye (ts11/10-F/45).

Data Collection
All data collected prior to wk 22 were designated as belonging to age interval I;
all data collected from wk 22 - 44 was designated as belonging to age interval II; and all
data collected from wk 45 - 57 were designated as belonging to interval III. Individual
BW was recorded at 20 wk (interval I), at 24, 32, and 43 wk (interval II), and at 47 and
56 wk of age (interval III) in both trials 1 and 2. Egg production was recorded daily and
analyzed weekly (weekly EP) from wk 23 (when Control treatment EP reached
approximately 10%) through wk 44 (interval II) and from wk 45 through wk 55 (interval
III) and was expressed as percent hen-day EP. Furthermore, the total number of eggs
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produced per hen (total hen EP) from onset of lay through 55 wk (across all 3 intervals),
and within intervals II (wk 22-44) and interval III (wk 45-55) separately, were likewise
determined. In order to include all eggs that were laid prior to 10 % EP, the calculation
of total hen EP across all 3 intervals was initiated when the first egg was laid (onset of
lay). Age of onset of lay ranged between 18 and 21 wk. Total hen EP was calculated as
total daily numbers of eggs produced as a percentage of total daily numbers of hens for
each replicate group.
Beginning on wk 23 (when Control treatment EP reached approximately 10 %),
eggs were collected 2 d per wk to determine egg weight (EW), eggshell breaking strength
(ESS), and percentage incidences of eggshell pimpling (ESP), egg blood spots (EBS),
and egg meat spots (EMS). Egg weight, ESS, ESP, EBS, and EMS determinations were
recorded weekly in both trials from 23 to 57 wk of age. These determinations were made
on all the same eggs that were produced within the 2 d time period. The ESS of each egg
was determined by the technique described by Reece and Lott (1976), and ESP, EBS, and
EMS incidences were determined using methods described by Branton et al., (1997). For
determination of eggshell weight per unit of eggshell surface area (SWUSA), a total of 10
eggs per pen were weighed at 20, 24, 32, 43, and 46 wk of age in both trials. The eggs
used for SWUSA measurements were different from the eggs used for determination of
EW, ESS, ESP, EBS, and EMS. Determination of SWUSA was according to the
procedure described by Peebles et al., (1994). All the above egg and eggshell
determinations were recorded on the same day that the eggs were collected.
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Statistical Analysis
A completely randomized experimental design, with trial as a block, was
employed. Data prior to wk 22 (age interval I), from wk 22-44 (age interval II), and from
wk 45-57 (age interval III) were analyzed separately. The data of both trials were pooled
then analyzed together. Therefore, the results from both trials were not reported
independently but were reported over both trials. Trial was considered as a random
effect. All data within each age interval were subjected to a repeated measures analysis if
parameters were examined at multiple age periods in an age interval. Otherwise, data
(i.e. total hen EP) obtained within and across age interval was subjected to 1-way
ANOVA.
In the first age interval, Controls and the ts11/10 treatment group were compared.
In the second age interval, Controls and those having had ts11/10 and ts11/10-F/22
inoculations were compared. In the third age interval, Control, ts11/10, ts11/10-F/22, and
ts11/10-F/45 groups were compared. Individual sample data within each of these
replicate units were averaged prior to analysis. Least-squares means were compared in
the event of significant global effects (Steel and Torrie, 1980). Global effects and
differences among least-squares means were considered significant at P ≤ .05. All data
were analyzed using the MIXED procedure of SAS software (SAS Institute, 2003).
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RESULTS AND DISCUSSION
All initial mycoplasmal cultures obtained from 5-wk old pullets, as well as SPA
tests were negative for both M. gallisepticum and M. synoviae. As described by Zander
(1984), M. gallisepticum is already established on many multi-age farms, and
transmission from mature hens to replacement pullets ensures its existence. Therefore, in
this study, birds were also later tested to ensure the absence of disease transmission
between treatment groups. The aforementioned cultures and SPA tests were repeated at
27 and 51 wk. Throughout the 2 trials these sample tests on all 4 treatment groups
showed that Control birds remained Mycoplasma–free (negative for both M.
gallisepticum and M. synoviae), whereas the 3 vaccinated groups resulted in positive
broth cultures, with FA and SPA results being positive for M. gallisepticum and negative
for M. synoviae. The SPA and FA tests confirmed systemic infections in M.
gallisepticum-inoculated birds, whether inoculated with the ts11- or F-strains of M.
gallisepticum. Nevertheless, there was no significant difference in mortality between M.
gallisepticum-free and M. gallisepticum-inoculated birds in either trial. More
specifically, no significant age or treatment main effects or age by treatment interactions
were found for bird mortality in any of the 3 age intervals examined. The few mortalities
recorded had no apparent relationship to treatment application.
In large commercial multi-age layer facilities where depopulation followed by
disinfection is impractical, vaccination programs are the best protection (Bermudez and
Kalbac, 1988). Vaccination for diseases in animals is commonly practiced where the
disease is endemic (Barile, 1985). Furthermore, early vaccination allows for the early
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development of immunity to Mycoplasmas before EP begins. Therefore, in one of the
treatment groups of this study, an early pre-lay vaccination was employed, and in 2 of the
other treatments, the early vaccination was used in conjunction with later overlay
vaccinations in order to confer continued protection during lay. Despite these treatment
applications, only a main effect (P ≤ 0.04) due to hen age for BW was observed in
interval II; hen BW at wk 24, 32, and 43 were 1.34, 1.40, and 1.45 kg, respectively
(pooled SEM = 0.022). Hen BW at wk 23 and 43 were significantly greater than that at
wk 24, but BW at wk 32 and 43 were not significantly different. There was no treatment
effect at wk 20 in interval I, and there was no significant treatment main effect or age by
treatment interaction in interval II. In addition, there were no significant age or treatment
main effects or an age by treatment interaction for BW in interval III. These BW data are
consistent with those reported by Burnham et al., (2002), Peebles et al., (2007), and
Viscione et al., (2008). Burnham et al., (2002) found no affect of a 12 wk F-strain M.
gallisepticum inoculation on subsequent BW, Peebles et al., (2007) showed that BW was
not affected by inoculation of F-strain M. gallisepticum at either 12 or 22 wk of age, and
Viscione et al., (2008) noted no significant effects of F-strain M. gallisepticum
inoculation at either 22 or 45 wk of age on layer hen BW. No previous research has
reported the effects of pre-lay ts11-strain M. gallisepticum vaccinations on layer BW.
A hen age main effect was observed for weekly EP in interval III (wk 45-55; P ≤
0.01; data not shown); however, no significant treatment main effect or age by treatment
interaction was observed for weekly EP in interval III. Also, no significant effects of any
kind were observed for weekly EP in interval II. Furthermore, total hen EP across lay
(intervals I - III) and total hen EP within interval II and within interval III were not
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significantly affected by treatment. Although total hen EP within intervals II and III and
across all 3 intervals was not affected by treatment, treatment means within interval II
and interval III are provided in Table 1 for observation. In trials conducted by Branton et
al., (1997), no negative effects were noted in EP or EW for birds that were challenged
with F-strain M. gallisepticum prior to lay, when compared to control birds. The results
of Branton et al., (1997) support other research previously conducted (Yoder 1978, 1991)
and Mohammed et al., (1987) who reported that F-strain M. gallisepticum vaccination
can reduce the negative impact of natural M. gallisepticum infections in layer flocks.
However, in studies reported by Burnham et al., (2002), where egg-laying hens were
inoculated at 12 wk of age with F-strain M. gallisepticum, it was reported that there was a
decrease in total EP and that birds laid their first eggs approximately 1 wk later than
controls that received only sham inoculations. Furthermore, Peebles et al., (2008) noted
that F-strain M. gallisepticum inoculations given at either 12 or 22 wk of age decreased
EP at the beginning of lay.
The lack of a pre-lay ts11-strain M. gallisepticum inoculation influence on EP in
the current study suggests that the possible negative effect of a pre-lay F-strain M.
gallisepticum inoculation on EP, as observed by Burnham et al., (2002) and Peebles et
al., (2008), might be avoided by using a ts11/10 pre-lay vaccination program. This
suggestion is supported by results from a study similar to the current one conducted by
Branton et al., (2000), in which a pre-lay inoculation of ts11-strain M. gallisepticum
alone was used. It was determined in that study that there were no significant differences
in EP or other egg and eggshell quality parameters between the ts11-strain M.
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gallisepticum vaccinated birds and controls, which indicated that a pre-lay ts11 vaccine
had no negative impact on overall layer performance.
In a study reported by Branton et al., (1988), where layer hens were inoculated
with F-strain M. gallisepticum at 45 wk of age, there was a significant decrease in EP
compared to control birds that were not vaccinated. This was in agreement with earlier
work published by Carpenter et al., (1981), who found that layers maintained free from
M. gallisepticum infection laid an average of 8.7 eggs/ hen housed more than did flocks
that were vaccinated with F-strain M. gallisepticum at 45 wk of age. The results of
Branton et al., (1988), Carpenter et al., (1981), and Peebles et al., (2008) demonstrate
further potential negative impacts of 22 and 45 wk F-strain M. gallisepticum inoculations
on performance. Because EP was not affected by the usage of ts11/10-F/22 or ts11/10F/45 vaccine treatments in the current 2 trials, it is also suggested that a pre-lay tsll/10
vaccination may help to prevent a significant drop in hen day EP when F-strain M.
gallisepticum vaccination overlays are given at either 22 or 45 wk. A pre-lay tsll/10
inoculation might serve to reduce the negative impacts of F-strain M. gallisepticum
inoculations given during lay.
An age by treatment interaction was observed for EW (P ≤ 0.04) in interval II
(Table 2.) At wk 27, EW was significantly larger in the ts11/10-F/22 treatment group
compared to the Control and ts11/10 treatment groups. This was opposite to that at wk
38, where the Control and ts11/10 treatment birds had a greater EW than the ts11/10-F/22
birds. At wk 37, the Control and ts11/10-F/22 birds had a higher EW than the ts11/10
treatment group. There were no significant age or treatment main effects or age by
treatment interactions in interval III. It has been noted that EW was unaffected by
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inoculations with ts11-strain M. gallisepticum at 10 wk (Branton et al., 2000), F-strain M.
gallisepticum at 12 wk (Burnham et al., 2002), F-strain M. gallisepticum at 12 and 22 wk
(Peebles et al., 2008), and F-strain M. gallisepticum at 22 and 45 wk (Viscione et al.,
2008). Branton et al., (1988) did find that F-strain M. gallisepticum inoculated at 45 wk
increased EW over a 15-wk period, but this was noted in only 1 of 2 trials. Also,
Burnham et al., (2002) found that the percentage of eggs belonging to the USDA
undersized egg category decreased at 19 wk but later increased at 20 and 21 wk after a 12
wk F-strain M. gallisepticum inoculation. The inconsistent results of these
aforementioned studies do not convincingly demonstrate that EW is susceptible to the
various inoculation regimens described involving ts11- and F-strains of M. gallisepticum.
However, despite the apparent innocuousness of a ts11/10 vaccination on EP,
consideration should be given to possible subsequent effects that a ts11/10 vaccination
might have on EW. This is suggested in this study because of the reduction in EW of the
ts11/10 treatment group relative to the Control group at wk 37. Furthermore, these
current data indicate that an overlay of F-strain M. gallisepticum at 22 wk may lead to
respective increases and decreases in EW at 27 and 38 wk in birds that had been given
ts11-strain M. gallisepticum vaccinations at 10 wk.
The effects of prelay and wk 22 F-strain M. gallisepticum inoculations on ESS,
ESP, EBS, and EMS have not been previously investigated. Nevertheless, F-strain M.
gallisepticum vaccinations at 45 wk (Branton et al., 1988) and ts11-strain M.
gallisepticum vaccinations at 10 wk of age (Branton et al., 2000) have been reported to
have no effect on these same parameters. However, in the current study, significant ageby- treatment interactions were observed for ESP (P ≤ 0.05; Table 3) and EBS (P ≤ 0.05;
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Table 4) in interval III. At wk 53, ESP was significantly higher for the ts11/10-F45
treatment group than for the Control or ts11/10-F/22 treatment groups. The ESP of the
ts11/10 treatment was not significantly different from the other 3 treatment groups. At
wk 56, the ts11/10-F/45 treatment group had a significantly higher ESP than the Control,
ts11/10, or ts11/10-F/22 treatment groups. Conversely, at wk 57, the ts11/10-F/45
treatment group was significantly lower than the Control or ts11/10 treatment group;
however, the ts11/10-F/22 group was not significantly different from the other 3 groups.
For EBS at wk 54, the incidence was higher for the ts/10-F/22 treatment when compared
to the Control, ts11/10, and ts11/10-F/45 treatment groups. However, at wk 56, the
ts11/10-F/45 treatment group had a significantly higher incidence of EBS than did the
other 3 groups. There were no significant effects of any kind for ESP or EBS in interval
II, for ESS or EMS in interval II or III, or for SWUSA in any of the 3 time intervals. The
egg and eggshell quality parameters selected for these trials reflected the functionality of
the ovary and specific segments of the oviduct as described by Branton et al., (2000).
However, ESS, EMS, and SWUSA were not affected, and EW, ESP, and EBS were
affected inconsistently by the combined vaccine treatments.
In conclusion, although possible effects of the combined vaccinations on EW,
ESP, and EBS should be considered, they had no recurrent negative impact on egg and
eggshell quality in the present study. Furthermore, the pre-lay ts11/10 vaccination
appeared to prevent a decrease in EP when F-strain M. gallisepticum was given during
lay. These results suggest that an overlay of F-strain M. gallisepticum on pre-lay ts11
vaccinated birds does not adversely impact layer performance. Each of the vaccine
treatments examined in this study had specific strengths and weaknesses. As noted in
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earlier work, the individual use of ts11- or F-strain M. gallisepticum vaccinations may
respectively have an adverse effect on EP or may not confer continued protection against
field strain M. gallisepticum infections. However, the ts11 and F-strain M. gallisepticum
vaccine treatment combinations may overcome some of the weaknesses that pre-lay
vaccines of ts11- or F- strains of M. gallisepticum may have if given alone. The pre-lay
ts11- and lay F-strain M. gallisepticum vaccine combination shows promise as research
continues to develop new and better vaccine protocols to eliminate the negative impacts
of Mycoplasma vaccination. It is suggested that in order to better establish the protective
benefits of a dual vaccination approach, this study should be followed by one using a
virulent M. gallisepticum challenge during lay.
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TABLE 3.1. Total hen egg production (EP) of commercial layers in shaminoculated control (Control), ts11 M. gallisepticum at 10 wk
(ts11/10), ts11 M. gallisepticum at 10 wk with 22 wk F-strain
M. gallisepticum overlay (ts11/10-F/22), and ts11 M. gallisepticum
at 10 wk with 45 wk F-strain M. gallisepticum overlay (ts11/10F/45) treatment groups within age intervals II (wk 22–44) and III
( wk 45–55)1
Age Interval
Inoculation Treatment
II2
III3
------------(%)-------------Control
85.2
73.4
ts11/10
81.9
74.5
ts11/10-F/22
81.3
63.1
ts11/10-F/45
----70.2
1
n = 4 replicate units for calculation of mean within each interval and inoculation
treatment group.
2
SEM based on pooled estimate of variance = 2.63.
3
SEM based on pooled estimate of variance = 3.64.
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TABLE 3.2. Egg weight (EW) of commercial layers in sham-inoculated control
(Control), ts11 M. gallisepticum at 10 wk (ts11/10) and ts11
M. gallisepticum at 10 wk with 22 wk F-strain M. gallisepticum
overlay (ts11/10-F/22) treatment groups at 27, 37, and 38 wk of
age1,2
Weeks of Age
Inoculation Treatment
27
37
38
-----------------------(g)--------------------56.3a
56.8a
Control
50.7b
ts11/10
50.8b
53.9b
56.0a
a
a
ts11/10-F/22
53.1
55.9
52.9b
a,b
Means within a column with no common superscript differ significantly (P ≤
0.05).
1
n = 4 replicate units for calculation of mean within each hen age and inoculation
treatment group.
2
SEM based on pooled estimate of variance = 0.75.
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TABLE 3.3. Eggshell pimpling incidence (ESP) of commercial layers in shaminoculated control (Control), ts11 M. gallisepticum at 10 wk
(ts11/10), ts11 M. gallisepticum at 10 wk with 22 wk F-strain
M. gallisepticum overlay (ts11/10-F/22), and ts11 M. gallisepticum
at 10 wk with 45 wk F-strain M. gallisepticum overlay (ts11/10F/45) treatment groups at 53, 56, and 57 wk of age1,2
Weeks of Age
Inoculation Treatment
53
56
57
-----------------------(%)--------------------0.223b
0.365a
Control
0.290b
ts11/10
0.389ab
0.273b
0.280a
b
b
ts11/10-F/22
0.301
0.250
0.268ab
ts11/10-F/45
0.502a
0.410a
0.143b
a,b
Means within a column with no common superscript differ significantly (P ≤
0.05).
1
n = 4 replicate units for calculation of mean within each hen age and inoculation
treatment group.
2
SEM based on pooled estimate of variance = 0.0600.
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TABLE 3.4. Egg blood spot incidence (EBS) of commercial layers in shaminoculated control (Control), ts11 M. gallisepticum at 10 wk
(ts11/10), ts11 M. gallisepticum at 10 wk with 22 wk F-strain
M. gallisepticum overlay (ts11/10-F/22), and ts11 M. gallisepticum
at 10 wk with 45 wk F-strain M. gallisepticum overlay (ts11/10F/45) treatment groups at 54 and 56 wk of age1, 2
Weeks of Age
Inoculation Treatment
54
56
----------------(%)---------------0.041b
Control
0.000b
ts11/10
0.016b
0.018b
a
ts11/10-F/22
0.183
0.025b
ts11/10-F/45
0.018b
0.161a
a,b
Means within a column with no common superscript differ significantly (P ≤
0.05).
1
n = 4 replicate units for calculation of mean within each hen age and inoculation
treatment group.
2
SEM based on pooled estimate of variance = 0.0300.
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CHAPTER IV
EFFECTS OF TIME SPECIFIC F-STRAIN MYCOPLASMA GALLISEPTICUM
INOCULATION OVERLAYS ON PRE-LAY TS11-STRAIN MYCOPLASMA
GALLISEPTICUM INOCULATION ON BLOOD CHARACTERISTICS OF
COMMERCIAL LAYING HENS

ABSTRACT
It has been established that Mycoplasma gallisepticum is a cause of great concern
to commercial egg producers with multi-age layer facilities complexes. Vaccination
programs have been implemented by many commercial egg producers to minimize egg
production losses due to infection with wild strains of M. gallisepticum. When F-strain
M. gallisepticum vaccine is given pre-lay, EP losses are decreased and the layer is
protected from the more virulent strains of M. gallisepticum. The F-strain M.
gallisepticum vaccine was the first live vaccine licensed for use in the United States;
however, it is not completely apathogenic. Other vaccine strains (ts11 and 685) that are
apathogenic have been licensed for use more recently. It has been proven that F-strain M.
gallisepticum vaccine can displace more pathogenic strains of M. gallisepticum. Neither
ts11 or 685 vaccine strains have been proven to displace wild type M. gallisepticum In
the present study, two trials were conducted to determine the effects of two currently
available live Mycoplasma gallisepticum vaccines (ts11 and F-strains) when used in
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combination. The following 4 inoculation treatments were utilized: 1) sham inoculation
at 10 wk of age, 2) ts11 at 10 wk, 3) ts11 at 10 wk overlaid by F at 22 wk, and 4) ts11 at
10 wk overlaid by F at 45 wk. Effects of vaccinations with the ts11 and F-strain M.
gallisepticum on the blood characteristics of commercial Single Combed White Leghorn
laying hens were investigated throughout lay. Variables measured in both trials were
whole blood hematocrit, plasma protein, and serum cholesterol, triglycerides and
calcium. No significant age or treatment main affects or age by treatment interactions
were observed for any of the observed blood parameters except for serum calcium. Mean
calcium levels were higher in the ts11/10 and ts11/-F/22 treatments in comparison to
controls between 23 and 44 weeks of age. Overall it suggests that ts11 vaccination at 10
wk of age alone or combined with the F-strain vaccine overlays at either 22 or 45 wk did
not adversely affect the blood of the treated birds.
(Key words: blood, hematology: commercial layer, F-strain Mycoplasma gallisepticum,
ts11-strain Mycoplasma gallisepticum)

INTRODUCTION
Vaccine programs have been implemented by egg producers maintaining multiage layer facilities to prevent losses from Mycoplasma gallisepticum (Carpenter et al.,
1981; Mohammed et al., 1987; Kleven, 1998). Three live M. gallisepticum vaccines have
been licensed for use to help prevent/control M. gallisepticum outbreaks (Evans et al.,
1992; Ley et al., 1997). The F-strain M. gallisepticum vaccine strain has predominantly
been used because of its proven ability not only to protect layers from field strains, but

55

also to displace more virulent field strains of M. gallisepticum and has a lower bird to
bird transmission rate (Levisohn and Kleven, 1981; Kleven et al., 1990).
The F-strain M. gallisepticum vaccine, however, is not completely apathogenic
(Lin and Kleven, 1982) and the spread to M.gallisepticum-free turkey and chicken farms
has been reported (Ley et. al., 1993, Turner and Kleven, 1998). Apathogenic strains ts11
and 685 M. gallisepticum are considered to be safer than F-strain vaccines with little to
no potential of spreading from bird to bird (Levisohn and Kleven, 1981; Kleven et al.,
1990). The ts11 and 685-strains of vaccine have not proven to displace wild type M.
gallisepticum (Kleven, 1998). Furthermore, these strains may not confer continued
protection as does the F-strain throughout lay (Yoder, 1978, 1991; Mohammed et al.,
1987).
Differential leukocyte counts of birds after exposure to Mycoplasma species have
been described (Kerr and Olson, 1970; Branton et al., 1997); however, further
characterization studies of the blood from birds infected with F-strain M. gallisepticum
have just recently been initiated (Burnham et al., 2003) with no literature available for
blood characteristics when birds are vaccinated with ts-11 strain M. gallisepticum
vaccine. More testing is needed to determine if combinations of vaccines can lessen the
impact of pre-lay F-strain M. gallisepticum vaccination on layer blood characteristics.
Therefore, the objective of the current study was to determine the effects of pre-lay ts11strain M. gallisepticum inoculations and time specific F-strain M. gallisepticum
inoculation overlays administered during lay on blood characteristics of commercial
laying hens.
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MATERIALS AND METHODS

Pullet Housing and Management
Two trials were performed using Hy-Line W-36 pullets that were obtained at 1 d
of age from a commercial source that was monitored and certified free of both M.
gallisepticum and M. synoviae (USDA-APHIS-VS, 2003). Chickens were vaccinated at
10 d of age for infectious bursal disease via the drinking water. At 5 wk of age, 20
randomly selected chickens were tested for antibodies to both M. gallisepticum and M.
synoviae using both the serum plate agglutination and the hemagglutination-inhibition
tests (Yoder, 1975) and swabs were obtained from the choanal cleft (Branton et al., 1984)
and placed into tubes containing Frey’s broth medium (Frey et al.,1968) supplemented
with an additional 0.15 thallium acetate and 106 IU penicillin-G/mL. Tubes were
incubated at 37о C for 30 d or until the phenol red indicator reaction occurred in the
media. A sample from those that changed color was then inoculated onto Frey’s-based
agar and incubated at 37 C. Colonies with morphology suggestive of Mycoplasma species
were examined by an agar plate fluorescent antibody test (Baas and Jasper, 1972) that
used direct labeling of colonies stained with anti-F-strain M. gallisepticum polyclonal
antibodies produced in rabbits and labeled with fluorescein isothiocyanate (Kleven,
1981).
Pullets were placed on clean dry litter in a conventional house until 10 wk of age.
A daily artificial lighting schedule followed a 13 L:11 D cycle. One 75-W incandescent
light bulb was used to illuminate each 8.4 m2 of floor space, providing a calculated
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intensity at bird level of 35.5 lx. Feed and water were provided for ad libitum
consumption in each trial. At 10 wk of age, 11 pullets were randomly selected and placed
in each of 16 negative pressure fiberglass biological isolation units (1.16 m2). The units
were housed in a previously described poultry disease isolation facility (Branton and
Simmons, 1992). Hen numbers were reduced to 10 per unit at point-of-lay (22 wk of
age) so that bird density was 0.116 m2 / bird for the duration of each trial. At 18 wk of
age, the length of the artificial lighting schedule was increased 15 min/d until a cycle of
16 h and 15 min of light per 7 h and 45 min of dark was achieved. Chickens were
maintained on that schedule through the remainder of each of the trials. For the entirety
of each trial, chickens had ad libitum access to feed and water. Pullet and layer diets
were formulated to meet or exceed NRC (1994) recommendations. Ingredient
percentages and calculated analyses of the diets were as described by Burnham et al.,
(2002). No medications were administered during either trial.

Treatments
Four experimental treatment groups were used. Each treatment group consisted
of 4 isolation units containing 10 birds each for a total of 40 birds per treatment group.
Treatment one (Controls) received no M. gallisepticum inoculation but were shaminoculated via eye-drop in the right eye with sterile Frey’s media. Treatment 2 contained
birds that were eye-drop vaccinated in the right eye with ts11-strain M. gallisepticum at
10 wk of age (ts11/10). Birds belonging to treatment 3 received ts11-strain M.
gallisepticum via eye-drop at 10 wk of age followed by a 22 wk overlay vaccination via
eye-drop in the left eye with F-strain M. gallisepticum (ts11/10-F/22). Treatment 4
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consisted of birds given ts11 strain M. gallisepticum at 10 wk of age via eye drop in the
right eye followed by a 45 wk overlay vaccination of F-strain M. gallisepticum via eye
drop in the left eye (ts11/10-F/45).

Data Collection
Birds were bled from the left wing vein from two hens per isolation unit. In each
trial, hen blood was drawn and harvested at the same time of day at 22, 24, 32, 43, and 55
wk of age. Results were recorded at 22, 24, 32, and 43 wk (interval I), and at and 55 wk
of age (interval II) in both trials 1 and 2. Effects of vaccinations with the ts11 and Fstrain M. gallisepticum on the blood characteristics of commercial Single Combed White
Leghorn laying hens were investigated throughout lay. Variables measured in both trials
were whole blood hematocrit (HCT), plasma protein (PP), and serum cholesterol (SC),
triglycerides (ST), and calcium (SCA). Hematocrit was expressed as percentage blood
packed cell (primarily red blood cell) volume, was determined through use of capillary
tubes that were centrifuged in a micro-HCT centrifuge and were then read with a
microcapillary reader. Serum cholesterol and ST expressed in milligrams per deciliter and
PP expressed in grams per deciliter were determined by placing 10 μL of serum or
plasma for each test on test slides, which were analyzed on a Kodak Ektachem DT-60
analyzer5 as described by Latour et al., (1996). Similarly, SCA concentrations expressed
in milligrams per deciliter were determined by placing 10 μL of serum on a test slide
which was analyzed on a Kodak Ektachem DTSC module analyzer5, according to
procedures of Tietz (1986). Control analyses were performed to assure that each sample
was in the appropriate test range for accurate analysis.
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Statistical Analysis
A completely randomized experimental design, with trial as a block, was
employed. Data from wk 22-44 (age interval I), and from wk 45-56 (age interval II) were
analyzed separately. The data of both trials were pooled then analyzed together.
Therefore, the results from both trials were not reported independently but were reported
over both trials. Trial was considered as a random effect. All data within each age
interval were subjected to a repeated measures analysis because parameters were
examined at multiple age periods in each age interval
In the first age interval, Controls and those having had ts11/10 and ts11/10-F/22
inoculations were compared. In the second age interval, Control, ts11/10, ts11/10-F/22,
and ts11/10-F/45 groups were compared. Individual sample data within each of these
replicate units were averaged prior to analysis. Least-squares means were compared in
the event of significant global effects (Steel and Torrie, 1980). Global effects and
differences among least-squares means were considered significant at P ≤ 0.05. All data
were analyzed using the MIXED procedure of SAS software (SAS Institute, 2003).

RESULTS AND DISCUSSION
All initial mycoplasmal cultures obtained from 5-wk old pullets, as well as SPA
tests were negative for both M. gallisepticum and M. synoviae. As described by Zander
(1984), M. gallisepticum is already established on many multi-age farms, and
transmission from mature hens to replacement pullets ensures its existence. Therefore, in
this study, birds were also later tested to ensure the absence of disease transmission
between treatment groups. Cultures and SPA test results on Control birds remained
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negative throughout the 2 trials for both M. gallisepticum and M. synoviae. The
aforementioned tests were repeated throughout the trial. These sample tests for all 4
treatment groups showed that Controls remained Mycoplasma - free, whereas the 3
vaccinated groups resulted in positive broth cultures with FA and SPA results being
positive for M. gallisepticum and negative for M. synoviae. Throughout the study, SPA
and FA tests confirmed systemic infections in M. gallisepticum-inoculated birds, whether
the inoculation was with the ts11- or F-strains of M. gallisepticum
Previous studies have suggested that M. gallisepticum moves through the blood
and has the ability to colonize the liver, as well as the reproductive organs in the bird.
Estrogen release and the onset of egg production in laying hens drastically increases liver
metabolism (Lorentz et al., 1938) and its production of neutral lipids (Heald and Badman,
1963), ST and phospholipids (Dashti et al., 1983). Eventually, these components are
destined for yolk lipid deposition (Nimpf and Schneider, 1991; Walzem et al., 1999).
Colonization of the liver by F-strain MG (F-strain M. gallisepticum) may negatively
affect liver metabolism (Sahu and Olson, 1976). M. gallisepticum infections are often
subclinical unless a secondary infection is present or outside stressors are present.
Manifestations of M. gallisepticum infections usually occur in the respiratory system and
lesions become extensive when complicated by other bacteria. The birds in this
experiment were housed in biological isolation chambers and not exposed to other
infective agents that could cause secondary infections or any outside stressors.
A treatment main affect (P ≤ 0.02) was observed for SCA in response to the prelay ts/11-F/22 strain M. gallisepticum inoculation in interval II. Mean SCA for control,
ts11/10, and ts11/10-F/22, treatments were 22.5, 26.7, and 28.4 mg/dL, respectively
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(Pooled SEM = 1.50). Mean SCA levels were significantly higher in the ts11/10 and
ts11/10-F/22 treatment groups in comparison to controls. Neither Peebles et al., (2007)
nor Burnham et al., (2002a, 2003) reported changes in SCA; however, in this study, there
was a significant increase in SCA in interval I for the treated birds. Nevertheless, the
change of SCA at that time does not appear to be impacting the performance of the birds
under these controlled conditions. It would be useful to repeat this experiment in a
commercial facility where the layer hens were exposed to normal stressors and diseases.
It is possible that the increase of SCA could contribute to weaker bones if excessive SCA
is being pulled from the bones. According to Burnham et al., (2003), in trials where birds
were vaccinated with F-strain vaccine at 12 wk of age and maintained under the same
aforementioned conditions, HCT increased at 8 wk after challenge suggesting a
compensatory polycythemic response the to the F-strain vaccination. Hematocrit levels
returned to those of the controls, after this time, indicating that the birds adjusted through
other physiological means to the F-strain vaccination stressor. In a previous report
(Burnham et al., 2002a), these same birds also exhibited a subsequent delay in onset of
lay and a decrease in total egg production in response to F-strain inoculation. In the
present study where ts11 vaccine was given at 10 wk and F-strain vaccine was either
given as an overlay at 22 wk or 45 wk, no significant treatment or age main affects or age
by treatment interactions for HCT were observed when comparing each of the treatment
groups with control birds. This in turn suggests that none of the treatment vaccinations
increase stress on the layer hens.
When comparing the HCT results in this study to the aforementioned study
(Burnham et al., 2002a), it appears that the 10 wk ts11 vaccination may have prevented
62

the stress response to either of the subsequent F-strain vaccinations. When a stressor
such as F-strain M. gallisepticum is introduced, ST may become elevated in response to
the infection. An elevation in ST is known to be a common response to the presence of
infectious disease agents (Guyton and Hall, 1996). Burnham et al., (2003) under the
same experimental conditions reported significant changes in each of the observed blood
characteristics at some point when F-strain vaccine was given alone. In the present study,
there were no significant age or treatment main effects or age by treatment interactions
for ST or PP in either trial or for SCH in either trial.
An increase in PP and HCT which is often the result of dehydration has been
reported by Burnham et al., (2003), to occur in response to pre-lay F strain M.
gallisepticum ; however, this study did not observe an increase in either PP or HCT. This
suggests that ts11/10 vaccination may prevent the dehydration that causes changes in PP
and HCT (Boyd, 1981; Warriss et al., 1997). This further suggests that the 10 wk ts11
vaccination may prevent stress from the F-strain vaccinations given either at 22 or 45 wk
of age. The results of the current study, when observing EP and blood characteristics
suggests that the possible stress of a 12 wk F-strain M. gallisepticum inoculation on EP
and blood characteristics, as observed by Burnham et al., (2002), might be avoided by
using a ts11/10 pre-lay vaccination program.
In conclusion, although possible effects of the combined vaccinations on blood
characteristics should be considered, they had no significant negative impacts on blood
characteristics in the present study. Each of the vaccine treatments examined in this
study had specific strengths and weaknesses; however, the ts11 and F-strain M.
gallisepticum vaccine treatment combinations may overcome some of the weaknesses
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that ts11 or F- strains of M. gallisepticum may have if given alone. This vaccine
combination shows promise as research continues to develop new and better vaccine
protocols to eliminate the negative impacts of Mycoplasma vaccination.
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CHAPTER V
EFFECTS OF TIME SPECIFIC F-STRAIN MYCOPLASMA GALLISEPTICUM
INOCULATION OVERLAYS ON PRE-LAY TS11- STRAIN MYCOPLASMA
GALLISEPTICUM INOCULATION ON DIGESTIVE AND REPRODUCTIVE
ORGAN CHARACTERISTICS OF COMMERCIAL EGG LAYING HENS
ABSTRACT
Outbreaks of Mycoplasma gallisepticum infections can have devastating affects
on commercial layer facilities. Three live vaccines are now available to control M.
gallisepticum outbreaks. Experimental inoculation with the F-strain of Mycoplasma
gallisepticum between 8 and 18 wk of age is known to affect reproductive performance in
commercial layers. Two trials were conducted to observe the effects of 2 currently
available live Mycoplasma vaccines (ts11- and F-strains) used in conjunction on digestive
and reproductive organs. In the present study, the following 4 inoculation treatments were
utilized: 1) sham inoculation at 10 wk of age, 2) ts11 at 10 wk, 3) ts11 at 10 wk overlaid
by F at 22 wk, and 4) ts11 at 10 wk overlaid by F at 45 wk. Necropsy at the end of both
trials using two birds per replication unit to observe the results on inoculated with liver
weight, liver lipid and moisture contents, ovary weight, ovarian follicular hierarchy, and
the weights, lengths, and histologies of the infundibulum, magnum, isthmus, uterus, and
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vagina. In both trials, treatment groups showed no significant change in the average
number of mature (diameter ≥ 12 mm) ovarian follicles in comparison to controls
(Key words: layer, liver, Mycoplasma gallisepticum, reproductive tract, small intestine)

INTRODUCTION
Mycoplasma gallisepticum is primarily a respiratory pathogen of meat-type
chickens and turkeys, and a reproductive pathogen of table egg chickens. The impact of
M. gallisepticum outbreaks, the ease of disease transmission and resulting systemic
infection causes M. gallisepticum to be worrisome organism for egg layer facilities
maintaining multiage layer facilities. Vaccination programs are presently being used to
prevent egg production (EP) losses and control outbreaks of the more virulent strains.
Three live vaccines are currently licensed for use in the United States. M. gallisepticum
F-strain has been licensed for use the longest and has been proven to protect layers from
wild strain M. gallisepticum, but is mildly pathogenic. More recently the two apathogenic
strains are ts11-strain M. gallisepticum and 685-strain M. gallisepticum were licensed for
use in the United States. These vaccines show virtually no bird to bird transmission, but
have not been proven to displace wild type M. gallisepticum (Kleven et al., 1998) or
confer continued protection throughout lay (Yoder, 1978, 1991; Mohammed et al., 1987).
Mycoplasma gallisepticum has the ability to not only colonize the respiratory tract
of layers, but also, the liver and reproductive organs in the bird. It is often asymptomatic
unless a secondary infection is involved or outside stressors such as ammonia, dust,
crowding, cold/hot temperatures. Interactions with other viruses and bacteria that can
occur under normal growing conditions can exacerbate and confuse the symptoms of M.
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gallisepticum infections (Saif et al.,1970, Jordan; 1972, Springer et al, 1974;Kleven et al.,
1998).
More testing is needed to determine if combinations of vaccines can lessen the
impact of pre-lay F-strain M. gallisepticum vaccination. Therefore, the objective of the
current study was to determine the effects of pre-lay ts11-strain M. gallisepticum
inoculations and time specific F-strain M. gallisepticum inoculation overlays
administered during lay on the performance characteristics of commercial laying hens.

MATERIALS AND METHODS

Pullet Housing and Management
Two trials were performed using Hy-Line W-36 pullets that were obtained at 1 d
of age from a commercial source that was monitored and certified free of both M.
gallisepticum and M. synoviae (USDA-APHIS-VS, 2003). Chickens were vaccinated at
10 d of age for infectious bursal disease via the drinking water. At 5 wk of age, 20
randomly selected chickens were tested for antibodies to both M. gallisepticum and M.
synoviae using both the serum plate agglutination and the hemagglutination-inhibition
tests (Yoder, 1975) and swabs were obtained from the choanal cleft (Branton et al., 1984)
and placed into tubes containing Frey’s broth medium (Frey et al., 1968) supplemented
with an additional 0.15 thallium acetate and 106 IU penicillin-G/mL. Tubes were
incubated at 37о C for 30 d or until the phenol red indicator reaction occurred in the
media. A sample from those that changed color was then inoculated onto Frey’s-based
agar and incubated at 37о C. Colonies with morphology suggestive of Mycoplasma
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species were examined by an agar plate fluorescent antibody test (Baas and Jasper, 1972)
that used direct labeling of colonies stained with anti-F-strain M. gallisepticum polyclonal
antibodies produced in rabbits and labeled with fluorescein isothiocyanate (Kleven,
1981).
Pullets were placed on clean dry litter in a conventional house until 10 wk of age.
A daily artificial lighting schedule followed a 13 L:11 D cycle. One 75-W incandescent
light bulb was used to illuminate each 8.4 m2 of floor space, providing a calculated
intensity at bird level of 35.5 lx. Feed and water were provided for ad libitum
consumption in each trial. At 10 wk of age, 11 pullets were randomly selected and placed
in each of 16 negative pressure fiberglass biological isolation units (1.16 m2). The units
were housed in a previously described poultry disease isolation facility (Branton and
Simmons, 1992). Hen numbers were reduced to 10 per unit at point-of-lay (22 wk of
age) so that bird density was 0.116 m2 / bird for the duration of each trial. At 18 wk of
age, the length of the artificial lighting schedule was increased 15 min/d until a cycle of
16 h and 15 min of light per 7 h and 45 min of dark was achieved. Chickens were
maintained on that schedule through the remainder of each of the trials. For the entirety
of each trial, chickens had ad libitum access to feed and water. Pullet and layer diets
were formulated to meet or exceed NRC (1994) recommendations. Ingredient
percentages and calculated analyses of the diets were as described by Burnham et al.,
(2002). No medications were administered during either trial.
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Treatments
Four experimental treatment groups were used. Each treatment group consisted
of 4 isolation units containing 10 birds each for a total of 40 birds per treatment group.
Treatment one (Controls) received no M. gallisepticum inoculation but were shaminoculated via eye-drop in the right eye with sterile Frey’s media. Treatment 2 contained
birds that were eye-drop vaccinated in the right eye with ts11-strain M. gallisepticum at
10 wk of age (ts11/10). Birds belonging to treatment 3 received ts11-strain M.
gallisepticum via eye-drop at 10 wk of age followed by a 22 wk overlay vaccination via
eye-drop in the left eye with F-strain M. gallisepticum (ts11/10-F/22). Treatment 4
consisted of birds given ts11 strain M. gallisepticum at 10 wk of age via eye drop in the
right eye followed by a 45 wk overlay vaccination of F-strain M. gallisepticum via eye
drop in the left eye (ts11/10-F/45).

Data Collection
At the end of each trial (wk 56), 2 birds from each replicate unit were euthanized
by cervical dislocation, their organs were removed, and the following parameters were
determined: liver weight, color, and moisture and lipid content; ovary weight, mature
follicle number (those that are ≥ 12 mm in diameter); total oviduct weight and length,
total small intestine weight and length; oviduct segments (infundibulum, magnum,
isthmus, and vagina) weights and lengths, and small intestine segments (duodenum,
jejunum, and ileum), weights and lengths; total oviduct and small intestine weights were
calculated as percentages of BW. Furthermore, oviduct and small intestine segment
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weights were calculated as percentages of BW and total organ weight and oviduct and
small intestine segment lengths were calculated as percentages of total organ length. The
number of mature follicles in an ovary was assigned a category from zero to six, where
zero indicates the absence of mature follicles, and where six is the number of maximum
follicles recorded. The percentage of birds in each unit possessing zero, one, two, three,
four, five, or six follicles was calculated. Livers were examined for color and for
incidence of FLHS. Three categories were used for liver color and for incidence of
FLHS. Three categories were used for liver color assignment: neutral, red, and yellow.
The number of birds in each unit possessing a particular liver color was expressed as a
percentage of total number of birds examined. Also, birds with normal livers or those
exhibiting FLHS were calculated as percentages of the total number of birds in each unit.

Statistical Analysis
A completely randomized experimental design, with trial as a block, was
employed. The data of both trials were pooled then analyzed together. Therefore, the
results from both trials were not reported independently but were reported over both
trials. Trial was considered as a random effect. All data was subjected to 1-way
ANOVA. Individual sample data within each of these replicate units were averaged prior
to analysis. Least-squares means were compared in the event of significant global effects
(Steel and Torrie, 1980). Global effects and differences among least-squares means were
considered significant at P ≤ .05. All data were analyzed using the MIXED procedure of
SAS software (SAS Institute, 2003).
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RESULTS AND DISCUSSION
All initial mycoplasmal cultures obtained from 5-wk old pullets, as well as SPA
tests, were negative for both M. gallisepticum and M. synoviae. Cultures and SPA test
results on Control birds remained negative throughout the 2 trials for both M.
gallisepticum and M. synoviae. The aforementioned tests were repeated at throughout the
experiment. These sample tests for all 4 treatment groups showed that Controls remained
Mycoplasma -free, whereas the 3 vaccinated groups resulted in positive broth cultures
with FA and SPA results being positive for M. gallisepticum and negative for M.
synoviae. Throughout the study, SPA and FA tests confirmed systemic infections in M.
gallisepticum-inoculated birds, whether the inoculation was with the ts11- or F-strains of
M. gallisepticum.
Vaccination for diseases in animals is commonly practiced where the disease is
endemic (Barile, 1985). Furthermore, early vaccination allows for the early development
of immunity to Mycoplasmas before egg production begins. No information is available
in the literature for digestive and organ characteristics for birds inoculated with ts11strain M. gallisepticum. Burnham et al., (2002b) reported that when F-strain M.
gallisepticum vaccination was given at 12 wk of age, egg production and other egg
characteristics beginning at onset of lay (18 wk of age) in birds inoculated with F -strain
M. gallisepticum at 12 wk of age were different from un-inoculated controls. Burnham et
al., (2002a) also reported that initiation of lay was delayed and that weekly egg
production after 42 wk and overall average weekly egg production were reduced in layer
hens inoculated with F -strain M. gallisepticum at 12 wk of age. Peebles et al., ( 2007)
reported that lower magnum weight in birds vaccinated with F-strain vaccine at 12 wk
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22. Percentage duodenal was also decreased in bird given the F-strain at 22 wk versus 12
wk.
M. gallisepticum can be transmitted both vertically (hen to eggs), (Glisson et al.,
1984), and horizontally (bird to bird) M. gallisepticum can be cultured from many
different organs in the layer hens. It has been cultured from the oviduct (Carlson and
Howell, 1967; Domermuth et al., 1967; Hitchner et al., 1980), liver, spleen, uterus, and
vagina (Sahu and Olson, 1976) and cloaca (Amin and Jordan, 1979; MacOwan et al.,
1983) of chickens. Branton et al., (1997) suggest that certain egg and eggshell quality
parameters can reflect the functioning of both ovary and special segments of oviduct.
The ability of M. gallisepticum to colonize liver and reproductive organs or the bird
suggests that possible quality parameters of egg production and quality could occur due
to organ damage Hepatic lipidosis referred to as fatty liver syndrome, often precedes
fatty liver hemorrhagic syndrome (FLHS), which has been associated with environmental
heat stress in birds (Riddell,1997). However, there was no treatment main effect for all
of parameters investigated at wk 56 except for the vagina as percent of the oviduct length.
There was a significant (P ≤ 0.007) main effect due to treatments for vagina length as a
percent of the total oviduct length. Mean vagina length as a percentage of total oviduct
length for the control, ts11/10, ts11/10-F/22, and ts11/-F/45, treatment groups were 5.49,
7.30, 5.64, and 5.36 percent respectively (Pooled SEM = 1.419). Mean vagina length as a
percentage of total oviduct length was significantly higher in the ts11/10 treatment group
in comparison to all the other 3 treatment groups.
In a study using ts11 vaccine, by Branton et al., (2000), egg production and egg
quality parameters selected reflected the functionality of the ovary and specific segments
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of the oviduct as described by Branton et al., (2000). No significant differences were
observed for EP, blood/meat spots, egg size, mortality, or HU scores. This suggested that
the ovary and various segments of the oviduct were not compromised by the ts11
vaccine. Furthermore, gross and histological changes were not observed upon necropsy.
These findings appear to agree with the results of the present study.
However, Burnham et al., (2002b) reported that hen inoculated with F-strain M.
gallisepticum at 12 wk had fewer mature ovarian follicles and a decreased magnal,
isthmal and vaginal proportion of the reproductive tract at trial termination (60 wk)
compared to F-strain M. gallisepticum free hens. Burnham suggested that the
establishment of systemic F-strain M.gallisepticum infections and long term changes
were the result of the disease rather than the F-strain M.gallisepticum vaccination.
The data in this trial differs from the above literature in that the significant
treatment main effect was observed for interval II was isolated in the vagina as percent of
the oviduct. The significance of the vagina to the overall performance is limited.
Therefore, it is suggested that inoculation regime did not have an adverse effect on
digestive or reproductive physiology.
Each of the vaccine treatments examined in this study had specific strengths and
weaknesses. However, it did appear that the ts11 and F-strain M. gallisepticum vaccine
treatment combinations overcame some of the weaknesses of pre-lay vaccines in which
ts11- or F- strains of M. gallisepticum were given alone. In conclusion, the pre-lay ts11and lay F-strain M. gallisepticum vaccine combination shows promise as research
continues to develop new and better vaccine protocols to eliminate the negative impacts
of Mycoplasma vaccination.
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CHAPTER VI
EFFECTS OF TIME SPECIFIC F-STRAIN MYCOPLASMA GALLISEPTICUM
INOCULATION OVERLAYS ON PRE-LAY TS11-STRAIN MYCOPLASMA
GALLISEPTICUM INOCULATION ON EGG YOLK COMPOSITIONS AND
HAUGH UNIT SCORES OF COMMERCIAL LAYING HENS

ABSTRACT
Mycoplasma infections are virtually endemic in multiage layer chicken flocks
with M. gallisepticum being the species of greatest concern to commercial egg producers.
Live M. gallisepticum vaccines are presently being used to help control M. gallisepticum
outbreaks. In the present study, two trials were conducted to compare the effects of two
currently available live Mycoplasma vaccines (ts11- and F-strains) used in conjunction.
The following 4 inoculation treatments were utilized: 1) sham inoculation at 10 wk of
age, 2) ts11 at 10 wk, 3) ts11 at 10 wk overlaid by F at 22 wk, and 4) ts11 at 10 wk
overlaid by F at 45 wk. In each trial at various ages between 23 and 57 wk of age,
percent yolk moisture, percent yolk lipid, percent yolk weight, percent albumen weight,
percent shell weight, and Haugh unit scores were assessed. At wk 32, percent yolk lipid
was increased in eggs belonging to the ts11 at 10 wk and ts11 at 10 wk overlaid by F at
22 wk treatment groups. Treatment main effects were observed for percent egg albumen
weight and Haugh unit scores. In comparison to controls, there was a significant
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decrease in percent albumen in eggs due to the ts11 at 10 wk and F at 22 wk treatment,
and there was a decrease in Haugh unit scores in the ts11 at 10 wk treatment. Percent
yolk moisture, percent egg yolk weight, and percent egg shell weight in layers were not
significantly affected by a 10 wk ts11 inoculation alone or in conjunction with
subsequent overlay inoculations of F during lay. It is therefore suggested that the 10 wk
inoculation of commercial layers with ts11 may reduce the negative impacts of a pre-lay
F inoculation on performance while providing protection against subsequent field strain
M. gallisepticum infections.
(Key words: commercial layer, egg characteristic, egg quality, F-strain Mycoplasma
gallisepticum, ts11-strain Mycoplasma gallisepticum)

INTRODUCTION
Mycoplasma gallisepticum, the pathogen responsible for chronic respiratory
disease in chickens, continues to be a costly problem for commercial table egg producers
maintaining multi-age layer houses (Yoder, 1991). Vaccination programs using live
whole cell vaccines are presently being used to control outbreaks and to help protect
flocks from field strains of M. gallisepticum. Three live vaccines are commercially
available for use in the United States. The most commonly used live vaccine is F-strain
M. gallisepticum (Barbour et al., 2000). The F-strain M. gallisepticum vaccine strain is
less virulent than many of the field strains and has a lower bird to bird transmission rate,
yet is able to displace the more virulent stains of M. gallisepticum (Levison and Kleven,
1981; Kleven et al., 1990). The predominate means of vaccination with live M.
gallisepticum vaccine strain in a commercial pullet setting is by coarse spray between 8
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to 10 wk of (Burnham et al., 2003) allowing pullets to receive a mild infection and
recover before coming into egg production (Yoder et al., 1984). Continuous use of Fstrain M. gallisepticum vaccines for replacement flocks in multi-age commercial layer
facilities has been proven to protect these flocks from field strains (Kleven et al., 1997).
The F-strain M. gallisepticum vaccine, however, is not totally apathogenic and has
been reported to infect M. gallisepticum free birds and turkeys (Evans et al., 1992; Ley et.
al., 1997). Once a bird is infected with M. gallisepticum, it is considered to be
chronically infected for life (Brown et al., 1995). In a controlled study in biological
isolation units, early vaccination with F-strain M. gallisepticum did not adversely affect
egg production (EP) (Branton et al., 1997). It has also been established that producers
that have used F-strain M. gallisepticum have also shown that no adverse effects on EP
occur when F-strain M. gallisepticum vaccines are given pre-lay (Burnham et al., 2003).
However, some field studies have determined that F-strain M. gallisepticum vaccination
can reduce EP when compared to Mycoplasma-free birds (Carpenter et al.,1981;
Mohammed et al., 1987; Branton et al., 1988). More recently, apathogenic whole cell
live vaccines, including ts11-strain M. gallisepticum and 685-strain M. gallisepticum,
have been licensed for use in layer chickens. These vaccines show virtually no bird to
bird transmission, but have not been proven to displace wild type M. gallisepticum
(Kleven et al., 1998). Furthermore, these strains may not confer continued protection
throughout lay as does the F-strain (Yoder, 1978, 1991; Mohammed et al., 1987).
Administration of the ts11 vaccine via eye drop, as per manufacturer instructions, is more
time consuming and labor intensive than spray vaccination.
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More testing is needed to determine if combinations of vaccines can lessen the
impact of pre-lay F-strain M. gallisepticum vaccination. Therefore, the objective of the
current study was to determine the effects of pre-lay ts11-strain M. gallisepticum
inoculations and time specific F-strain M. gallisepticum inoculation overlays
administered during lay on the egg quality of commercial laying hens.

MATERIALS AND METHODS

Pullet Housing and Management
Two trials were performed using Hy-Line W-36 pullets that were obtained at 1 d
of age from a commercial source that was monitored and certified free of both M.
gallisepticum and M. synoviae (USDA-APHIS-VS, 2003). Chickens were vaccinated at
10 d of age for infectious bursal disease via the drinking water. At 5 wk of age, 20
randomly selected chickens were tested for antibodies to both M. gallisepticum and M.
synoviae using both the serum plate agglutination and the hemagglutination-inhibition
tests (Yoder, 1975) and swabs were obtained from the choanal cleft (Branton et al., 1984)
and placed into tubes containing Frey’s broth medium (Frey et al., 1968) supplemented
with an additional 0.15 thallium acetate and 106 IU penicillin-G/mL. Tubes were
incubated at 37° C for 30 d or until the phenol red indicator reaction occurred in the
media. A sample from those that changed color was then inoculated onto Frey’s-based
agar and incubated at 37° C. Colonies with morphology suggestive of Mycoplasma
species were examined by an agar plate fluorescent antibody test (Baas and Jasper, 1972)
that used direct labeling of colonies stained with anti-F-strain M. gallisepticum polyclonal
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antibodies produced in rabbits and labeled with fluorescein isothiocyanate (Kleven,
1981).
Pullets were placed on clean dry litter in a conventional house until 10 wk of age.
A daily artificial lighting schedule followed a 13 L:11 D cycle. One 75-W incandescent
light bulb was used to illuminate each 8.4 m2 of floor space, providing a calculated
intensity at bird level of 35.5 lx. Feed and water were provided for ad libitum
consumption in each trial. At 10 wk of age, 11 pullets were randomly selected and placed
in each of 16 negative pressure fiberglass biological isolation units (1.16 m2). The units
were housed in a previously described poultry disease isolation facility (Branton and
Simmons, 1992). Hen numbers were reduced to 10 per unit at point-of-lay (22 wk of
age) so that bird density was 0.116 m2 / bird for the duration of each trial. At 18 wk of
age, the length of the artificial lighting schedule was increased 15 min/d until a cycle of
16 h and 15 min of light per 7 h and 45 min of dark was achieved. Chickens were
maintained on that schedule through the remainder of each of the trials. For the entirety
of each trial, chickens had ad libitum access to feed and water. Pullet and layer diets
were formulated to meet or exceed NRC (1994) recommendations. Ingredient
percentages and calculated analyses of the diets were as described by Burnham et al.,
(2002). No medications were administered during either trial.

Treatments
Four experimental treatment groups were used. Each treatment group consisted
of 4 isolation units containing 10 birds each for a total of 40 birds per treatment group.
Treatment one (Controls) received no M. gallisepticum inoculation but were sham87

inoculated via eye-drop in the right eye at 10 wk of age with sterile Frey’s media.
Treatment 2 contained birds that were eye-drop vaccinated in the right eye with ts11strain M. gallisepticum at 10 wk of age (ts11/10). Birds belonging to treatment 3
received ts11-strain M. gallisepticum via eye-drop in the right eye at 10 wk of age
followed by a 22 wk overlay vaccination via eye-drop in the left eye with F-strain M.
gallisepticum (ts11/10-F/22). Treatment 4 consisted of birds given ts11 strain M.
gallisepticum at 10 wk of age via eye drop in the right eye followed by a 45 wk overlay
vaccination of F-strain M. gallisepticum via eye drop in the left eye (ts11/10-F/45).
The tsll vaccine titers for both trials were 1.0 X 1010 colony forming units/mL
(CFU/mL). For trial 1, F-strain M. gallisepticum titers were 3.0 x 1010and 1.0 x 108
CFU/mL at wk 22 and 45, respectively. For trial 2, F-strain M. gallisepticum titers were
7.5 x 1011 CFU/mL for both inoculation overlays (wk 22 and 45).

Data Collection and Egg Parameters Measured
All data collected from wk 23-44 was designated as belonging to age interval I;
and all data collected from wk 45-57 were designated as belonging to interval II. Percent
yolk lipid (YL), percent yolk moisture (YM), percent egg yolk weight (PY), percent egg
albumen weight (PA), and percent shell weight (PSW) were determined in eggs at 24,
32, and 43 wk of age (interval I), and at 47 and 56 wk of age (interval II) in both trials 1
and 2. Beginning on wk 23 (when Control group EP reached approximately 10 %) in
both trials, eggs were collected weekly from 23 to 44 wk (interval I) and weekly from 45
to 57 wk (interval II) to determine egg Haugh unit scores (HU). For determination of the
above mentioned parameters, a total of 10 eggs were collected from each replicate unit
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for an accurate estimate of each parameter (Buss, 1984). If less than 10 eggs were
collected on a given d, the rest were collected the following d of the same wk. Egg
processing and determinations of HU and of fresh yolk and albumen weights were made
on the same day that eggs were collected. Eggshell (dried shell plus membranes) weight
was determined according to the procedure described by Brake et al., (1984). Egg
component (egg yolk, albumen, and shell) weights were expressed as percentages of total
egg weight. Haugh unit scores were determined using a Model EQM egg quality
management system (Technical Services and Supplies Limited, York, England)
according to the procedure of Branton (1988).

Quantification of Yolk Moisture and Lipid Content
For YM determinations, yolk samples (2 g) were dried in a commercial oven
(Chromalox Temperature Control, Edwin L. Wiegand Co. Pittsburgh, PA) according to
the procedure of Peebles et al., (1999). After samples were removed from the oven, they
were allowed 30 min to cool and the dry weights were recorded. Yolk moisture was
calculated as the difference between the fresh and dry weight of the sample and was
expressed as a percentage of fresh sample weight.
Yolk lipid was extracted according to the procedure described by Bligh and Dryer
(1959), and as modified by Latour et al., (1998). A 3 g sample of fresh yolk was
thoroughly mixed with 10 mL of methanol and 10 mL of chloroform in a 100 mL beaker.
Mixing was done by hand until the mixture was a pasty homogenate. Water (5 mL) was
added to the homogenate and the mixture was filtered through Whatman No. 1 filter
paper in a Coors Buchner funnel. The filtered mixture was pulled under vacuum suction
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into 50 mL centrifuge tubes. Additionally, the beaker that contained the original 3 g
sample was rinsed with 3 mL of chloroform to extract any additional yolk, and that liquid
was also poured through filter paper as described above. Centrifuge tubes were spun in a
Beckman JB-6 centrifuge (Beckman Instruments, Inc., Fullerton, CA 93634) for 15 mins
at 3000 rpm in order to separate the alcohol and lipid. The centrifuged samples contained
two well-defined layers (lower chloroform-lipid layer and upper methanol-water layer).
The upper layer was discarded and the lower chloroform-lipid layer was filtered through
a column of anhydrous sodium sulfate into a glass tube. The chloroform containing lipid
extract was placed into a V-Evap apparatus (Organomantion, Shrewsbury, MA 01545)
and dried with a stream of air. Dried lipid samples were weighed and the expression of
YL concentration was dry lipid sample weight as a percentage of total fresh yolk sample
weight.

Statistical Analysis
A completely randomized experimental design, with trial as a block, was
employed. Data from wk 23 - 44 (age interval I), and from wk 45 - 57 (age interval II)
were analyzed separately. The data of both trials were pooled then analyzed together.
Therefore, the results from both trials were not reported independently but were reported
over both trials. Trial was considered as a random effect. All data within each age
interval were subjected to a repeated measures analysis because parameters were
examined at multiple age periods in each age interval. In the first age interval, Controls
and those having had ts11/10 and ts11/10-F/22 inoculations were compared. In the
second age interval, Control, ts11/10, ts11/10-F/22, and ts11/10-F/45 groups were
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compared. Individual sample data within each of the replicate units were averaged prior
to analysis. Least-squares means were compared in the event of significant global effects
(Steel and Torrie, 1980). Global effects and differences among least-squares means were
considered significant at P ≤ 0.05. All data were analyzed using the MIXED procedure
of SAS software (SAS Institute, 2003).

RESULTS AND DISCUSSION
All initial mycoplasmal cultures obtained from 5-wk old pullets, as well as SPA
tests, were negative for both M. gallisepticum and M. synoviae. Cultures and SPA test
results on Control birds remained negative throughout the 2 trials for both M.
gallisepticum and M. synoviae. The aforementioned tests were repeated throughout the
entire study. These sample tests for all 4 treatment groups showed that Controls
remained Mycoplasma -free, whereas the 3 vaccinated groups resulted in positive broth
cultures with FA and SPA results being positive for M. gallisepticum and negative for M.
synoviae. There was no significant difference in mortality between M. gallisepticum- free
and M. gallisepticum - inoculated birds in either trial. Throughout the study, SPA and FA
tests confirmed systemic infections in M. gallisepticum-inoculated birds, whether the
inoculation was with the ts11- or F-strains of M. gallisepticum.
No significant age or treatment main effects or age by treatment interactions were
found for YM, PY, or PSW in either age interval examined. A hen age by treatment
interaction (P ≤ 0.05) was observed for YL (wk 24, 32, 43) in interval I (Table 1). In
comparison to Controls, YL was significantly higher in the ts11/10 and ts11/10-F/22
vaccination regimens at wk 32. However, no significant age or treatment main effects or
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age by treatment interaction was observed for YL in interval II. Also, no age or treatment
main effects or age by treatment interaction was observed for PA in interval I.
Furthermore, there was no significant age main effect or age by treatment interaction for
PA in interval II; however, there was a treatment main effect (P ≤ 0.05) for PA in interval
II (across 47 and 56 wk). Mean egg PA for Control, ts11/10, ts11/10-F/22, and ts11/10F/45 treatments in interval II were 59.5, 58.5, 57.2, and 60.1 %, respectively (pooled
SEM = 0.86). Egg PA at wk 47 and 56 was significantly lower for ts11/10-F/22
treatment birds than for Control and ts11/10-F/45 treatments, with the ts11/10 treatment
intermediate. For HU, there were no age or treatment main effects or age by treatment
interactions in interval I, and there was no significant age main effect or age by treatment
interaction in interval II. Nevertheless, a treatment main effect (P ≤ 0.05) was observed
for HU scores in interval II (45-57 wk). Mean HU for Control, ts11/10, ts11/10-F/22,
and ts11/10-F/45 treatments were 93.6, 91.8, 93.9 and 93.3, respectively (pooled SEM =
1.84). In interval II, mean HU for the ts11/10 treatment group was significantly lower
than that for the other 3 treatment groups. This result suggests that a prelay ts11-strain
M. gallisepticum inoculation alone may lower albumen quality during postpeak lay.
In comparison to Controls, significant increases in YL were observed at 32 wk in
birds administered either the ts11/10 or ts11/10-F/22 vaccination regimens. This result
suggests that the inoculation of ts11 M. gallisepticum at 10 wk may increase YL in eggs
up to 22 wk later. The basis for this effect is not clear, however, the synthesis, transport,
and uptake of lipid in the liver, blood, and ovary, respectively, cannot be precluded as
possible locations and means by which the ts11 M. gallisepticum organism may colonize
and influence YL. Furthermore, these data imply that a subsequent inoculation of F92

strain M. gallisepticum at 22 wk does not modify the effect of the ts11/10 treatment on
YL at 32 wk.
The distribution of fatty acids of various chain lengths is relatively constant in YL
and is related to their synthesis in the hens’ liver (Watkins and Kratzer, 1987; Watkins,
1995; Walzem, 1996; Speake and Thompson, 1999). Sturkie (1976) reported that
approximately 32% of total egg weight is yolk, 11% of total egg weight is shell, and 57%
of the total egg weight is albumen and that the egg weight is primarily the function of the
four albumen layers. Albumen is secreted in the magnum in response to the pressure of
the egg yolk. Sturkie (1976) also reported that the stimulation of albumen secretion is
proportional to the size of the egg yolk. Therefore, the total egg size is directly related to
ovarian follicular development consequently the smaller the egg yolk the smaller the total
egg weight. HU scores reflect the inner quality of the egg, specifically albumen quality.
The majority of the albumen formation occurs during the 2-3 hr the ovum remains in the
magnum (Johnson, 1986; Branton et. al., 1988). Mycoplasma gallisepticum has been
cultured from the liver (Sahu and Olson, 1976) and periovarian region (Fabricant and
Levine, 1963) of chickens. The liver is considered to be the primary source of lipid
production. The egg and eggshell quality parameters selected for these trials reflected the
functionality of the ovary and specific segments of the oviduct as described by Branton et
al., (2000). In a study using ts11 vaccine, by Branton et al., (2000), egg production and
egg quality parameters were evaluated. No significant differences were observed for EP,
blood/meat spots, egg size, mortality, or HU scores. This suggested that the ovary and
various segments of the oviduct were not compromised by the ts11 vaccine.
Furthermore, gross and histological changes were not observed upon necropsy.
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Branton et al., (1997) reported that EP and other egg characteristic in birds
inoculated with F-strain M. gallisepticum at 10 wk of age were not significantly different
than controls. It has, however, been proven that F-strain M. gallisepticum given late in
lay does reduce EP. These changes were the result of the disease rather than the
vaccination. In a more recent report by Burnham et al., (2002), using birds inoculated at
12 wk of age, EP was reported to be significantly different in the F-strain vaccinated
birds compared to the controls. Burnham et al., (2002) reported that onset of lay was
delay and that a significant decrease in EP occurred. It was reported that inoculated hens
had fewer mature ovarian follicles and a decreased magnal, isthmal and vaginal
proportion of the reproductive tract at trial termination (60 wk) compared to F-strain M.
gallisepticum free hens Burnham. Burnham suggested that the establishment of systemic
F-strain M. gallisepticum infections and long term changes were the result of the disease
rather than the F-strain M. gallisepticum vaccination. In further studies of yolk
characteristics (Burnham et al., 2003), a decrease in YL was observed at 22 wk in the Fstrain vaccinated birds suggesting that F-strain vaccination may inhibit YL disposition at
this time. Increased percentages of YL post peak, however, may represent a
compensatory increase in YL deposition in response to the earlier depression in YL.
Each of the vaccine treatments examined in this study had specific strengths and
weaknesses. However, it did appear that the ts11 and F-strain M. gallisepticum vaccine
treatment combinations overcame some of the weaknesses of pre-lay vaccines in which
ts11- or F- strains of M. gallisepticum were given alone. The results of this study suggest
that the combination of ts11 and F-strain M. gallispticum vaccinations may prevent a
decrease in HU scores late in lay that were observed as a result of the individual ts11/10
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treatment. Also, it appears that ts11 M. gallispticum vaccination at 10 wk prevented the
drop in EP when the F-strain M. gallispticum vaccine was given late in lay. Therefore,
the combination of ts11 and F-strain M. gallisepticum may result in a better outcome than
vaccinations with either strain alone. In conclusion, the pre-lay ts11- and lay F-strain M.
gallisepticum vaccine combination shows promise as research continues to develop new
and better vaccine protocols to eliminate the negative impacts of Mycoplasma
vaccination.
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TABLE 6.1. Percent yolk lipid concentration of eggs from commercial layers in shaminoculated control (Control), ts11 M. gallisepticum at 10 wk (ts11/10), and
ts11 M. gallisepticum at 10 wk with 22 wk F-strain M. gallisepticum
overlay (ts11/10-F/22) treatment groups at 24, 32, and 43 wk of age
(interval I)1,2.
Weeks of Age
24
32
43
-----------------------(%)--------------------Control
22.1
20.8b
22.1
a
22.1
ts11/10
20.5
23.2
ts11/10-F/22
21.9
23.4a
22.9
a,b
Means within a column with no common superscript differ significantly (P ≤
0.05).
1
n = 4 replicate units for calculation of mean within each hen age and inoculation
treatment group.
2
SEM based on pooled estimate of variance = 0.95.
Inoculation Treatment
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CHAPTER VII
SUMMARY

The primary goal of the present study was to investigate the effects of a ts11strain M. gallisepticum inoculation alone, and in conjunction with F-strain M.
gallisepticum overlays at 22 or 45 weeks of age during lay. F-strain M. gallisepticum has
previously been shown to negatively affect laying hens’ performances when given prelay or during post-peak lay, whereas ts11-strain M. gallisepticum inoculation
administered pre-lay has previously been shown to not exert these negative effects.
In this study, it was shown that a pre-lay ts11 vaccination had a broad range effect
on the physiology of the commercial layer without affecting overall performance. The
effects on the bird’s physiology included effects in the oviduct, blood, egg yolk, and egg
albumen. More specifically, the pre-lay ts11/10 vaccination had unassociated effects on
relative vaginal length, SCA, YL, and HU. Furthermore, the timing of an overlay
vaccination using F-strain M. gallisepticum during lay had varied effects on some of the
aforementioned physiological parameters without affecting overall performance. The
effects of the timing of F-strain M. gallisepticum overlays included those on SCA, Yl,
and HU. Both the early (wk 22) and late (wk 45) F-strain M. gallisepticum overlays
ameliorated the adverse effects of the pre-lay ts11 vaccine on HU and the late overlay
decreased YL and SCA in comparison to the early overlay.
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These results confirm that pre-lay ts11-strain M. gallisepticum inoculations may
be suitable for pre-lay F-strain M. gallisepticum inoculations, and the F-strain M.
gallisepticum overlays during lay on pre-lay ts11-strain M. gallisepticum may also
provide continual protection without eliciting any subsequent suppressive affects on
performance. The data from this study indicates that using ts11-strain M. gallisepticum
in conjunction with F-strain M. gallisepticum does not negatively affect laying hen
performance. Furthermore, this inoculation combination offers benefits above the use of
those achieved through either inoculation alone. Also, because F-strain M. gallisepticum
is a more virulent strain, F-strain M. gallisepticum may offer stronger protection during
lay than ts11-strain M. gallisepticum. The results of this study would be of particular
interest in an industry setting in which flocks previously inoculated with ts11-strain M.
gallisepticum are acquired by a company comfortable with a traditionally used F-strain
M. gallisepticum inoculation regimen.
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